Methods and compositions for reduction of side effects of therapeutic treatments

ABSTRACT

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

CROSS REFERENCE

This application claims the benefit of provisional applications60/909,637 entitled Methods and Compositions for Reduction of SideEffects of Therapeutic Treatments filed Apr. 2, 2007; 60/956,296entitled Methods and Compositions for Reduction of Side Effects ofTherapeutic Treatments filed Aug. 16, 2007; and 60/956,657 entitledMethods and Compositions for Reduction of Side Effects of TherapeuticTreatments filed Aug. 17, 2007.

GOVERNMENT INTERESTS

Certain embodiments of the present invention were made under researchgrant numbers NIH NS34886 and NS 42091 from the National Institute ofHealth, who may have certain rights thereto.

BACKGROUND OF THE INVENTION

Many of the leading treatments for diseases lead to undesired sideeffects. For instance, levodopa, the standard for Parkinson's diseasetreatment, is associated with debilitating abnormal involuntarymovements or dyskinesias. These motor abnormalities may occur after onlya few months of treatment and affect the majority of patients within5-10 years. They can be quite incapacitating and represent a majorcomplication in Parkinson's disease management. Currently there are onlylimited therapeutic options for dyskinesias.

Parkinson's disease is extremely common amongst those over 65, and agegroup that, in North America, is predicted to rise from 12% to 24% overthe next 30 year. The overall prevalence of Parkinson's disease in thispopulation is in the order of 1.5-2% and increases with age. Therefore,additional treatments are needed for this disabling complication oflevodopa therapy.

SUMMARY OF THE INVENTION

The invention provides methods, compositions, and kits for the use ofnicotinic receptor modulator. For example the methods, compositions, andkits described herein are used to reduce or eliminate a side effect. Insome embodiments, the methods, compositions, and kits described hereinare used to reduce or eliminate a side effect of a dopaminergic agent.

In one aspect, the invention provides compositions including a nicotinicreceptor modulator. In some embodiments of this aspect, the inventionprovides a pharmaceutical composition including a nicotinic receptormodulator. In some embodiments, the invention includes pharmaceuticalcompositions where the nicotinic receptor modulator is present in anamount sufficient to decrease a side effect of a dopaminergic agent whenthe composition is administered to an animal. In some embodiments, theinvention includes pharmaceutical compositions where the nicotinicreceptor modulator is present in an amount sufficient to reduce oreliminate a side effect of a dopaminergic agent and to prevent or reducethe likelihood of addiction to the nicotinic receptor modulator when thecomposition is administered to an animal. The pharmaceuticalcompositions including a nicotinic receptor modulator are administeredthrough various routes of delivery further described herein. In someembodiments, the pharmaceutical compositions including a nicotinicreceptor modulator are administered orally to an animal. In someembodiments, the invention provides a solid pharmaceutical compositionfor oral administration containing an effective amount of a nicotinicreceptor modulator and a pharmaceutical excipient suitable for oraladministration. In some embodiments, the invention provides a liquidpharmaceutical composition for oral administration containing aneffective amount of a nicotinic receptor modulator and a pharmaceuticalexcipient suitable for oral administration.

In some embodiments of this aspect, the invention provides apharmaceutical composition including a dopaminergic agent and nicotinicreceptor modulator. In some embodiments, the invention includespharmaceutical compositions where the nicotinic receptor modulator ispresent in an amount sufficient to decrease a side effect of thedopaminergic agent when the composition is administered to an animal.

In some embodiments of this aspect, the nicotinic receptor modulatormodulates a nicotinic receptor in the brain. In some embodiments, thenicotinic receptor modulator modulates a nicotinic receptor in thestriatum or substantia niagra. In some embodiments, the nicotinicreceptor modulator modulates a nicotinic receptor comprising at leastone

subunit or a nicotinic receptor containing at least one α subunit and atleast one β subunit. In some embodiments, the α subunit is selected fromthe group consisting of α2, α3, α4, α5, α6, α7, α8, α9, and α10 and theβ subunit is selected from the group consisting of β2, β3 and β4. Insome embodiments, the nicotinic receptor modulator modulates a nicotinicreceptor comprising subunits selected from the group consisting of α4β2,α6β2, α4α6β2, α4α5β2 α4α6β2β3, α6β2β3 and α4α2β2.

In some embodiments of the composition, the nicotinic receptor modulatorin the composition includes a nicotinic receptor agonist. In someembodiments, the nicotinic receptor agonist in the composition isselected from the group consisting of a simple or complex organic orinorganic molecule, a peptide, a protein, an oligonucleotide, anantibody, an antibody derivative, an antibody fragment, a vitaminderivative, a carbohydrate, and a toxin. Examples of nicotinic receptoragonists include, but are not limited to, nicotine, conotoxinMII,epibatidine, A-85380, cytisine, lobeline, anabasine, SIB-1508Y,SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403,SSR180711, GTS-21 and varenicline. In some embodiments, the agonist isnicotine.

In some embodiments of the composition, the dopaminergic agent is adopamine precursor or a dopamine receptor agonist. Examples ofdopaminergic agents include, but are not limited to, levodopa,bromocriptine, pergolide, pramipexole, cabergoline, ropinorole,apomorphine or a combination thereof. In some embodiments, thedopaminergic agent is levodopa.

In some embodiments of the compositions of the invention, the sideeffect being treated includes tremors, headache, changes in motorfunction, changes in mental status, changes in sensory functions,seizures, insomnia, paresthesia, dizziness, coma and dyskinesias. Insome embodiments, the side effect is dyskinesias. In some embodiments ofthe compositions of the invention, the side effects are decreased atleast 30% compared to the side effects without the nicotinic receptormodulator. In some embodiments of the invention, the therapeutic effectof dopaminergic agent is increased an average of at least about 5%compared to the therapeutic effect without the nicotinic receptormodulator, when the composition is administered to an animal.

In some embodiments of the compositions of the invention, the nicotinicreceptor modulator is administered to an animal suffering or about tosuffer from a dopaminergic agent-induced side effect such that thenicotinic receptor modulator or a metabolite reaches an optimalconcentration in the blood, plasma and/or target tissues in the animalso the side effect can be decreased. In some embodiments the nicotinicreceptor modulator or a metabolite is in the bloodstream of the animalprior to the dopaminergic agent. In some embodiments, the nicotinicreceptor modulator or a metabolite is in the bloodstream of the animalafter the dopaminergic agent but prior to the beginning of thedopaminergic agent-induced side effect. In some embodiments, thenicotinic receptor modulator or a metabolite is in the bloodstream ofthe animal after the dopaminergic agent and after the animal is showingthe first signs of a dopaminergic agent-induced side effect. In someembodiments, the nicotinic receptor modulator or a metabolite is in thebloodstream of the animal after the dopaminergic agent and after theanimal is suffering of a dopaminergic agent-induced side effect.

In some embodiments, the nicotinic receptor modulator is administeredthrough pulsatile delivery. In some embodiments, the nicotinic receptormodulator is administered in an extended release or controlled releaseformulation. In some embodiments, the nicotinic receptor modulatorand/or the dopaminergic agent are administered in a multilayer tablet.

In some embodiments of the compositions of the invention, apharmaceutical composition includes the composition of the invention anda pharmaceutically acceptable excipient. In some embodiments of thecomposition, a molar ratio of the dopaminergic agent and the nicotinicreceptor modulator is about 0.001:1 to about 10:1. In some embodimentsof the composition, the dopaminergic agent is present in an amount ofabout 0.1 to about 1000 mg and the nicotinic receptor modulator ispresent in an amount of about 0.1 to about 2000 mg. In some embodiments,the nicotinic receptor modulator is nicotine. In some embodiments,nicotine is present at about 0.1 to about 100 mg. In some embodiments,nicotine is present at about 0.1 to about 10 mg. In some embodiments,nicotine is present at about 0.5 mg. In some embodiments of thecompositions of the invention, a pharmaceutical composition includes aneffective amount of levodopa and an amount of nicotine sufficient toreduce levodopa induced-dyskinesias and a pharmaceutically acceptablecarrier.

In some embodiments, a pharmaceutical composition includes a third agentalso used for the treatment of a side effect of the dopaminergic agent.In some embodiments, the side effect treated with the nicotinic receptormodulator and the third agent is the same side effect. In someembodiments, the side effects treated with the nicotinic receptormodulator and the third agent are different side effects. In someembodiments, the third agent is amantadine. In some embodiments, thepharmaceutical compositions of the invention include one or more agentsused in the art in combination with a dopamine agent treatment toachieve a therapeutic effect. For instance, in some embodiments, thepharmaceutical compositions of the invention include an agent such ascarbidopa, which blocks the conversion of levodopa to dopamine in theblood. In some embodiments, the pharmaceutical compositions of theinvention include a COMT Inhibitors, such as entacapone. In someembodiments, the pharmaceutical compositions of the invention include amonoamine oxidase type B (MAO-B) inhibitor such as selegiline.

In some embodiments of the compositions of the inventions, apharmaceutical composition includes an effective amount of levodopa, aneffective amount of carbidopa, an effective amount of nicotine capableof reducing levodopa-induced dyskinesias and a pharmaceuticallyacceptable carrier.

In some embodiments of the compositions of the inventions, apharmaceutical composition includes an effective amount of adopaminergic agent, an effective amount of nicotine and apharmaceutically acceptable carrier, where nicotine is present at about0.01 to about 10 mg.

In some embodiments of the compositions of the inventions, a solidpharmaceutical composition for oral administration includes nicotine anda pharmaceutically acceptable carrier, where nicotine is present atabout 0.01 mg to about 2.8 mg. In some embodiments of the compositionsof the invention, the amount of nicotine present is less than 3 mg.

In some embodiments of the compositions of the inventions, a multilayertablet includes an immediate release layer and a sustained releaselayer, where the immediate release layer comprises one or moretherapeutic agents independently selected from the group consisting ofnicotinic receptor agonist and dopaminergic agent, and the sustainedrelease layer comprises one or more therapeutic agents independentlyselected from the group consisting of nicotinic receptor agonist anddopaminergic agents. In some embodiments, the immediate release layer orthe sustained release agent further comprises a third agent. In someembodiments, the third agent is used to achieve a therapeutic effect incombination with the dopaminergic agent or to treat a side effect of thedopaminergic agent.

In some embodiments of the invention, a kit includes the composition ofthe invention and instructions for use of the composition.

In another aspect, the invention provides methods utilizing nicotinicreceptor agonist. In some embodiments of this aspect, the inventionprovides a method of treating an animal by administering to an animal aneffective amount of a nicotinic receptor agonist sufficient to reduce oreliminate a side effect of a dopaminergic agent. In some embodiments ofthis aspect, the invention provides a method of treating an animal byadministering to an animal an effective amount of a nicotinic receptoragonist sufficient to reduce or eliminate a side effect of adopaminergic agent and to prevent or reduce the likelihood of addictionto the nicotinic receptor modulator when the composition is administeredto an animal. In some embodiments, the nicotinic receptor modulator isadministered through various routes of delivery further describedherein. In one embodiment, the nicotinic receptor modulator isadministered orally to an animal.

In some embodiments of this aspect, the invention provides a method oftreating a condition by administering to an animal suffering from thecondition an effective amount of a dopaminergic agent and an amount of anicotinic receptor agonist sufficient to reduce or eliminate a sideeffect of the dopaminergic agent. In some embodiments, the agonistreduces or eliminates a plurality of side effects of the dopaminergicagent. In some embodiments, the dopaminergic agent and the nicotinicreceptor agonist are administered in a single composition. In someembodiments, the dopaminergic agent and the nicotinic receptor agonistare admixed in the composition.

In some embodiments of this aspect, the invention provides a method ofdecreasing a side effect of treatment with a dopaminergic agent byadministering to a human in need of a treatment with a dopaminergicagent an effective amount of nicotine in combination with thedopaminergic agent, where the dopaminergic agent and nicotine areadministered simultaneously to the human in an oral composition. In someembodiments, the dopaminergic agent and nicotine are administered in asingle composition. In some embodiments, the dopaminergic agent andnicotine are administered in different compositions. In someembodiments, the dopaminergic agent and nicotine are admixed in thecomposition.

In some embodiments of this aspect, the invention provides a method ofdecreasing levodopa-induced dyskinesias by administering to a human inneed of treatment an effective amount of nicotine in combination with aneffective amount of levodopa and an effective amount of carbidopa, wherethe amount of nicotine is sufficient to reduce the dyskinesias andwherein levodopa and nicotine are administered orally simultaneously tosaid human.

In some embodiments of the methods of the invention, the dopaminergicagent is present in an amount sufficient to exert a therapeutic effectand the nicotinic receptor agonist is present in an amount sufficient todecrease a side effect of the dopaminergic agent by an average of atleast about 30%, compared to the effect without the nicotinic receptoragonist. In some embodiments, the administration is oral administration.In some embodiments, the administration is transdermal administration.

In some embodiments of the methods of the invention, the nicotinicreceptor modulator is administered to an animal suffering or about tosuffer from a dopaminergic agent-induced side effect such that thenicotinic receptor modulator or a nicotinic receptor modulatormetabolite reaches an effective concentration in the blood, plasmaand/or target tissues in the animal so as to reduce or eliminate theside effects associated with the dopaminergic agent, where the effectiveconcentration is the concentration necessary to reduce or eliminate theside effect. In some embodiments, the nicotinic receptor modulator or ametabolite is present in the bloodstream of the animal prior to thedopaminergic agent. In some embodiments, the nicotinic receptormodulator or a metabolite is in the bloodstream of the animal after thedopaminergic agent but prior to the beginning of the dopaminergicagent-induced side effect.

In various embodiments, presence of the dopaminergic agent and thenicotinic receptor modulator or a metabolite thereof in the blood isregulated temporally and/or spatially. For example, each agent can beadministered at temporally different times (one before the other). Inaddition, the two agents can be administered at the same time but in adosage form which functions for regulate release of one versus the otherover a period of time (e.g., bi-layered tablet dosage form).

In some embodiments, the nicotinic receptor modulator or a metabolite ispresent in the bloodstream of the animal after the dopaminergic agentand after the animal exhibits the first signs of a dopaminergicagent-induced side effect. In some embodiments, the nicotinic receptormodulator or a metabolite is present in the bloodstream of the animalafter the dopaminergic agent and after the animal exhibits adopaminergic agent-induced side effect.

In some embodiments, the nicotinic receptor modulator is administeredthrough pulsatile delivery. In some embodiments, the nicotinic receptormodulator is administered in an extended release or controlled releaseformulation. In some embodiments, the nicotinic receptor modulator andthe dopaminergic agent are administered in a multilayer tablet.

In some embodiments of the methods of the invention, the nicotinicreceptor agonist in the composition is selected from the groupconsisting of a simple or complex organic or inorganic molecule, apeptide, a protein, an oligonucleotide, an antibody, an antibodyderivative, an antibody fragment, a vitamin derivative, a carbohydrate,and a toxin. Examples of nicotinic receptor agonists include, but arenot limited to, nicotine, conotoxinMII, epibatidine, A-85380, cytisine,lobeline, anabasine, SIB-1508Y, SIB-1553A, ABT-418, ABT-594, ABT-894,TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21 and varenicline. In someembodiments, the agonist is nicotine. In some embodiments of theinvention, the dopaminergic agent is a dopamine precursor or a dopaminereceptor agonist. Examples of dopaminergic agents include, but are notlimited to, levodopa, bromocriptine, pergolide, pramipexole,cabergoline, ropinorole, apomorphine or a combination thereof. In someembodiments, the dopaminergic agent is levodopa.

In some embodiments, the methods described herein include a third agentalso used for the treatment of a side effect of the dopaminergic agent.In some embodiments, the side effect treated with the nicotinic receptormodulator and the third agent is the same side effect. In someembodiments, the side effects treated with the nicotinic receptormodulator and the third agent are different side effects. In someembodiments, the third agent is amantadine. In some embodiments, themethods described herein include one or more agents used in the art incombination with a dopamine agent treatment to achieve a therapeuticeffect. For instance, in some embodiments, the methods described hereininclude an agent such as carbidopa, which blocks the conversion oflevodopa to dopamine in the blood. In some embodiments, the methodsdescribed herein include a COMT Inhibitors, such as entacapone. In someembodiments, the methods described herein include a monoamine oxidasetype B (MAO-B) inhibitor such as selegiline.

In some embodiments of the methods of the invention, the individualsuffers from a condition including Parkinson's disease, Alzheimer,dopa-responsive dystonia, cerebral palsy, postischemic contractiledysfunction, severe ovarian hyperstimulation syndrome, pediatricmovement disorders and non-oliguric renal failure.

In another aspect, the invention provides methods of treatingdyskinesias by administering to an animal in need of thereof an amountof a nicotinic receptor agonist sufficient to reduce or eliminate thedyskinesias.

In another aspect, the invention provides methods of treatingParkinson's disease by administering to an animal in need of thereof anamount of a nicotinic receptor agonist sufficient to reduce or eliminateParkinson's disease. In some embodiments, the invention provides methodsof treating Parkinson's disease by administering to an animal in need ofthereof an amount of a nicotinic receptor agonist sufficient to reduceor eliminate physiological symptoms associated with Parkinson's disease,notwithstanding that the patient may still be afflicted with Parkinson.

Other objects, features and advantages of the methods and compositionsdescribed herein will become apparent from the following detaileddescription. It should be understood, however, that the detaileddescription and the specific examples, while indicating specificembodiments, are given by way of illustration only, since variouschanges and modifications within the spirit and scope of the inventionwill become apparent to those skilled in the art from this detaileddescription.

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication or patent application was specificallyand individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings of which:

FIG. 1 depicts drug treatments schedule and behavioral testing periods.

FIG. 2 depicts a time course of the nicotine-induced decline inL-dopa-induced dyskinesias.

FIG. 3 depicts that overall dyskinesias were decreased by nicotinetreatment.

FIG. 4 depicts a graph showing that nicotine treatment decreased peakdyskinesias.

FIG. 5 depicts graphs showing that nicotine administration decreasedtotal levodopa-induced dyskinesias in levodopa-primed monkeys.

FIG. 6 depicts graphs showing that removal of nicotine increasedlevodopa-induced dyskinesias in levodopa-primed monkeys.

FIG. 7 depicts a graph showing that nicotine administration does notaffect Parkinsonism on or off L-dopa treatment.

FIG. 8 depicts schedule for treatment paradigms and behavioral testingin rats.

FIG. 9 depicts graphs showing time courses of nicotine treatment ontotal L-dopa-induced AIMs in 6-hydroxydopamine-lesioned rats.

FIG. 10 depicts graphs showing that nicotine treatment differentiallyreduces L-dopa-induced AIM components.

FIG. 11 depicts graphs showing that intermittent nicotine treatmentreduces L-dopa-induced abnormal involuntary movements (AIMs) in rats.

FIG. 12 depicts graphs showing that intermittent nicotine treatmentreduced individual AIM components in rats after L-dopa treatment.

FIG. 13 shows a crossover study depicting the effect of intermittentnicotine treatment via the drinking water on L-dopa-induced AIMs inrats.

FIG. 14 shows that continuous nicotine exposure via minipump reducesL-dopa-induced AIMs.

FIG. 15 shows that constant nicotine exposure via minipump reducedindividual AIM components after L-dopa treatment.

FIG. 16 shows a crossover study depicting the effect of constantnicotine exposure via minipump on L-dopa-induced AIMs.

DETAILED DESCRIPTION OF THE INVENTION

Reference will now be made in detail to particularly preferredembodiments of the invention. Examples of the preferred embodiments areillustrated in the following Examples section.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in theart to which this invention belongs. All patents and publicationsreferred to herein are incorporated by reference.

The invention provides compositions and methods. In some embodiments,the invention provides compositions and methods utilizing a nicotinicreceptor modulator, e.g., to reduce or eliminate a side effectassociated with dopaminergic agent treatment. In some embodiments, theinvention provides compositions and methods utilizing a combination of adopaminergic agent and a nicotinic receptor modulator. In someembodiments, the nicotinic receptor modulator reduces or eliminates aside effect associated with dopaminergic agent treatment. In someembodiments, the nicotinic receptor modulator is an agonist.Dopaminergic agents include a dopamine precursor or a dopamine receptoragonist. Examples of dopaminergic agents include levodopa,bromocriptine, pergolide, pramipexole, cabergoline, ropinorole,apomorphine or a combination thereof.

Nicotinic Receptor System

A. Striatal Nicotinic Cholinergic System

Localization of cholinergic neurons in striatum. Cholinergic neurons inthe striatum are large interneurons that comprise about 2% of theneuronal population. Although limited in number, these interneurons havelarge axonal arbors that provide for a very dense local innervation inboth the caudate and putamen. Indeed, high levels of acetylcholine, theacetylcholine synthesizing enzyme choline acetyltransferase and theacetylcholine degradative enzyme acetylcholinesterase are expressed inthe striatum. These cholinergic markers overlap with dopaminergicarbors, containing dopamine, the dopamine synthetic enzyme tyrosinehydroxylase and other dopaminergic markers that are also expressed at arelatively high density. Without being limited to any theory, theoverlapping distribution of the cholinergic and dopaminergic systemprovides the anatomical basis for a functional interaction between thesetwo neurotransmitters.

Nicotinic acetylcholine receptors in striatum. Striatal cholinergicinterneurons are tonically active with a resultant ongoing release ofacetylcholine that is regulated by multiple striatal systems includingglutamatergic, dopaminergic, GABAergic, serotonergic, and other inputs.Released acetylcholine interacts with nAChRs present on dopaminergic, aswell as other striatal neurons. These receptors are pentamericligand-gated ion channels composed only of α subunits (homomeric), or ofα and β subunits (heteromeric receptors). To date, six different α (α2,α3, α4, α5, α6, α7) and three different β (β2, β3, β4) subunits havebeen identified in the nigrostriatal pathway. These subunits combine toform nAChRs, with the primary subtypes in the striatum composed of α4β2*and α3/α6β2* subunits as well as a small population of homomeric α7nAChRs. (*The asterisks indicate that there are other subunits, some notyet identified that are also present and may be species dependent). Theα4β2* receptors are localized on dopaminergic terminals as well as otherneurons in the striatum and throughout the CNS. However, they are notpresent in the peripheral nervous system or skeletal muscle.Interestingly, α3/α6β2* receptor subtypes are selectively localized tothe dopaminergic nigrostriatal pathway, and only a limited number ofother brain areas, suggesting they may be of particular relevance tonigrostriatal function. These latter receptors (α3/α6β2*) are designatedas expressing α3 and/or α6 subunits, because both are present in monkeystriatum, and α-conotoxinMII, the ligand used to identify thesereceptors, interacts with both α3 and α6 nAChR subtypes. Without beinglimited to any theory, the presence of different receptor populations ondopaminergic neurons raises the possibility that select subtypes may bemore directly linked to the development of dyskinesias and theantidyskinetic properties of nicotine. Such knowledge would allow forthe development of nAChR agonists more specifically targeted toameliorating dyskinesias.

Striatal nicotinic receptor activation results in dopamine release.Endogenously released acetylcholine or exogenously applied agents suchas nicotine and nicotinic agonists are known to stimulate nAChRs ondopaminergic neurons, with increases in dopamine release in the striatumunder both in vitro and in vivo conditions. Agonist-evoked dopaminerelease in striatum occurs in response to stimulation of nAChR subtypescomposed of α4β2* and α3/α6β2* subunits. Without being limited to anytheory, the antidyskinetic effect of nicotine as described herein may beassociated with changes in dopamine release after stimulation of α4β2*and/or α3/α6β2* nAChRs.

B. Striatal Dopaminergic System and its Involvement in Reduction ofDopaminergic Agent Treatment Side Effects.

One of the neurotransmitter systems responsible for the development ofdopaminergic agent treatment side effects, such as dyskinesias, inparkinsonian animals or individuals with Parkinson's disease is thedopaminergic system itself. For instance, D1, D2 and D3 receptoragonists all induce dyskinesias, indicating that multiple receptorsubtypes are involved. There appears to be an imbalance in activity ofthe two striatal output pathways with dyskinesias, possibly throughactivation of D1 and inhibition of D2 receptors on the direct andindirect pathway, respectively, with D3 receptors possibly exerting amodulatory influence. Despite a clear requirement for dopamine receptorstimulation, there are no consistent changes in the D1, D2 or D3receptors themselves with dyskinesias. Without being limited to anytheory, such findings most likely indicate that levodopa-induced changesmay not occur at the receptor level, but involve downstream signalingevents. Recent data suggest that D1 receptors, possibly through enhancedG-protein coupling, may play a role in dopaminergic agent-induceddyskinesias, while D2 receptors may be more relevant in mediating theantiparkinsonian action of dopaminergic agents. G-proteins aremembrane-associated molecules that couple ligand-activatedneurotransmitter receptors to intracellular second messenger systems. D1dopamine receptor-stimulated striatal G-protein coupling was enhanced instriatal tissue from monkeys with dopaminergic agent-induced dyskinesiascompared to controls. In addition, recent data show that there is alsoenhanced μ-opioid receptor coupling with dopaminergic agent-induceddyskinesias, another measure linked to activation of the D1 directdopaminergic pathway. Increases have also been identified incyclin-dependent kinase 5 (Cdk5) and dopamine cAMP-regulatedphosphoprotein (DARPP-32), an important site for signal transductionintegration in striatum. A down-regulation of striatal D1 receptor/NMDAreceptor complexes has also been observed with the development ofdyskinesias. Without being limited to any theory, the ability ofnicotine to reduce dopaminergic agent-induced dyskinesias is likelyrelated to normalization of the imbalance between striatal outputpathways and modulation of signaling mechanisms.

In addition to changes in molecular markers linked to activation of theD1 direct dopaminergic pathway, the development of dopaminergicagent-induced dyskinesias is also associated with alterations incellular function. In vivo and in vitro electrophysiological studieshave been used to investigate basal ganglia function under normalconditions and in animals with nigrostriatal damage. This approachoffers the advantage that it allows for a determination of changes insynaptic function and neuronal excitability not readily detectable usingbiochemical techniques. One in vitro preparation that has provedparticularly useful to study the cellular mechanisms altered withdopaminergic agent-induced dyskinesias, are corticostriatal slices fromrat brain. Brain slices at the level of the globus pallidus havegenerally been used as they incorporate many of the structures presentin basal ganglia motor circuits. This includes glutamatergic inputs fromthe cortex that densely innervate striatal medium spiny GABAergicneurons and are a determinant of neuronal activity in striatalprojection neurons. Synaptic plasticity, defined as long-lasting changesin the efficacy of synaptic transmission, has been identified incorticostriatal slices in vitro in the form of long-term potentiation(LTP), long-term depression (LTD) and depotentiation. In slices fromunlesioned rats, high-frequency stimulation (HFS) of glutamatergiccorticostriatal afferent fibers can induce both LTD and LTP in striatalmedium spiny neurons, most likely due to a release of striatal glutamatewhich triggers dopamine release. Stimulation of both D1 and D2 receptorsis required for the induction of LTD, whereas these two receptorsubtypes play opposing roles in LTP. This plasticity at corticostriatalsynapses is sensitive to both dopamine exposure and nigrostriatal damagewith a loss of plasticity with lesioning. Moreover, it has been shownthat chronic L-dopa treatment modulates plasticity. It was found thatL-dopa treatment restores LTP in rats both without and with dyskinesias,but that low frequency stimulation (LFS)-induced responses(depotentiation) were specifically lost in dyskinetic rats. In addition,it was found that exogenous dopamine induced a slow-onset LTP incorticostriatal slices from L-dopa-treated dyskinetic animals but LTD inslices from nondyskinetic animals. Without being limited to any theory,these data suggest that dopamine-mediated activity-dependent synapticpotentiation may be altered in dyskinetic compared to nondyskineticanimals. Accumulating evidence thus suggests that abnormal plasticity atcorticostriatal synapses may be involved in the development ofdopaminergic agent-induced dyskinesias.

Interestingly, these inventors have recently found that nicotinetreatment modulates synaptic plasticity in corticostriatal slices fromnonhuman primates. In particular, it restores long-term depression (LTD)that is lost as a result of nigrostriatal damage. Without being limitedto any theory it is possible that that nicotine modulates synapticplasticity and promotes functional restoration also in animals withdopaminergic agent-induced dyskinesias and that this mechanism underliesits antidyskinetic effect.

Nicotinic Receptor Modulators

In one aspect, the invention provides compositions and methods utilizinga nicotinic receptor modulator, e.g., to reduce or eliminate a sideeffect associated with dopaminergic agent treatment. Modulators may beany suitable modulator.

In some embodiments, the nicotinic receptor modulator modulates anicotinic receptor in the brain. In some embodiments, the nicotinicreceptor modulator modulates a nicotinic receptor in the striatum orsubstantia niagra. In some embodiments, the nicotinic receptor modulatormodulates a nicotinic receptor comprising at least one α subunit or anicotinic receptor containing at least one

subunit and at least one β subunit. In some embodiments, the α subunitis selected from the group consisting of α2, α3, α4, α5, α6, α7, α8, α9,and α10 and the β subunit is selected from the group consisting of β2,β3 and β4. In some embodiments, the nicotinic receptor modulatormodulates a nicotinic receptor comprising subunits selected from thegroup consisting of α4β2, α6β2, α4α6β2, α4α5β2 α4α6β2β3, α6β2β3 andα4α2β2. In some embodiments, the nicotinic receptor modulator modulatesa nicotinic receptor comprising at least one α subunit selected from thegroup consisting of α4, α6, and α7.

In some embodiments, modulators useful in the invention are nicotinicreceptor antagonist. The term “antagonist” as used herein refers to amolecule having the ability to inhibit a biological function of a targetpolypeptide. Accordingly, the term “antagonist” is defined in thecontext of the biological role of the target polypeptide. Whilepreferred antagonists herein specifically interact with (e.g. bind to)the target, molecules that inhibit a biological activity of the targetpolypeptide by interacting with other members of the signal transductionpathway of which the target polypeptide is a member are alsospecifically included within this definition. Antagonists, as definedherein, without limitation, include antibodies, antibody derivatives,antibody fragments and immunoglobulin variants, peptides,peptidomimetics, simple or complex organic or inorganic molecule,antisense molecules, oligonucleotide decoys, proteins, oligonucleotide,vitamin derivatives, carbohydrates, and toxins.

In some embodiments, modulators useful in the invention are nicotinicreceptor agonist. The term “agonist” as used herein refers to a moleculehaving the ability to initiate or enhance a biological function of atarget polypeptide. Accordingly, the term “agonist” is defined in thecontext of the biological role of the target polypeptide. Whilepreferred agonists herein specifically interact with (e.g. bind to) thetarget, molecules that enhance a biological activity of the targetpolypeptide by interacting with other members of the signal transductionpathway of which the target polypeptide is a member are alsospecifically included within this definition. Agonists, as definedherein, without limitation, include antibodies, antibody derivatives,antibody fragments and immunoglobulin variants, peptides,peptidomimetics, simple or complex organic or inorganic molecule,antisense molecules, oligonucleotide decoys, proteins, oligonucleotide,vitamin derivatives, carbohydrates, and toxins.

The nicotinic receptor agonist of the invention may be any ligand thatbinds to and activates the nicotinic receptor, thereby resulting in abiological response. The potential of a given substance to act as anicotinic receptor agonist may be determined using standard in vitrobinding assays and/or standard in vivo functionality tests.

Nicotinic receptor agonist for use according to the invention includethose substances described in e.g. WO 92/21339 (Abbott), WO 94/08992(Abbott), WO 96/40682 (Abbott), WO 9746554 (Abbott), WO 99/03859(AstraZeneca), WO 96/15123 (Salk Institute) WO 97/19059 (Sibia), WO00/10997 (Ortho-McNeil), WO 00/44755 (Abbott), WO 00/34284 (Synthelabo),WO 98/42713 (Synthelabo), WO 99/02517 (Synthelabo), WO 00/34279(Synthelabo), WO 00/34279 (Synthelabo), WO 00/34284 (Synthelabo), EP955301 (Pfizer), EP 857725 (Pfizer), EP 870768 (Pfizer), EP 311313(Yamanouchi Pharmaceutical), WO 97/11072 (Novo Nordisk), WO 97/11073(Novo Nordisk), WO 98/54182 (NeuroSearch), WO 98/54181 (NeuroSearch), WO98/54152 (NeuroSearch), WO 98/54189 (NeuroSearch), WO 99/21834(NeuroSearch), WO 99/24422 (NeuroSearch), WO 00/32600 (NeuroSearch), WOPCT/DK00/00211 (NeuroSearch), WO PCT/DK00/00202 (NeuroSearch), or theirforeign equivalents.

Examples of nicotinic receptor agonist according to the inventioninclude nicotine, ethyl nicotine,3-ethynyl-5-(1-methyl-2-p-yrrolidinyl)pyridine (SIB-1765F),4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thi-o]phenol (SIB-1553),(S)-3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-pyridine (SIB-1508Y),4′-methylnicotine or (2S-trans)-3-(1,4-dimethyl-2-pyrrolidin-yl)pyridine(Abbott), 2-methyl-3-[(2S)-2-pyrrolidinylmethoxy]-pyridine (ABT-089),3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-isoxazole (ABT-418),5-[(2R)-2-azetidinylmethoxy]-2-chloro-Pyridine (ABT-594), 3-PMP or3-(1-pyrrolidinyl-methyl)pyridine (RJ Reynold),(3E)-N-methyl-4-(3-pyridi-nyl)-3-buten-lamine (RJR-2403), anabasine or3,4,5,6-tetrahydro-2,3′-bipyr-idine (RJ Reynold), 5-fluoronicotine or(S)-5-fluoro-3-(1-methyl-2-pyrroli-dinyl)pyridine (RJ Reynold), MCC or2-(dimethylamino)ethyl methylcarbamate (Lundbeck), ethyl arecolone or1-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl-)-1-propanone (Lilly), orisoarecolone or 1-(1,2,3,6-tetrahydro-1-methyl-4- -pyridinyl)ethanone(Lilly), AR-R 17779 (AstraZeneca), epibatidine, GTS-21,1-(6-chloro-3-pyridyl)-homopiperazine, 1-(3-pyridyl)15 homopiperazine,1-(5-ethynyl-3-pyridyl)-homopiperazine, conotoxinMII, epibatidine,A-85380, cytisine, lobeline or salts, free bases, racemates orenantiomers thereof.

Other nicotinic receptor agonists include choline esterase inhibitors(e.g., that increase local concentration of acetylcholine), derivativesof epibatidine that specifically bind the neuronal type of nicotinicreceptors (with reduced binding to the muscarinic receptor) and havingreduced deleterious side-effects (e.g., Epidoxidine, ABT-154, ABT418,ABT-594; Abbott Laboratories (Damaj et al. (1998) J. Pharmacol Exp.Ther. 284:1058 65, describing several analogs of epibatidine of equalpotency but with high specificity to the neuronal type of nicotinicreceptors). Further nicotinic receptor agonists of interest include, butare not necessarily limited to, N-methylcarbamyl andN-methylthi-O-carbamyl esters of choline (e.g., trimethylaminoethanol)(Abood et al. (1988) Pharmacol. Biochem. Behav. 30:403 8); acetylcholine(an endogenous ligand for the nicotinic receptor); and the like.

In one embodiment, the nicotinic receptor agonist is nicotine (which isunderstood from to include nicotine derivatives and like compounds).Nicotine's chemical name is S-3-(1-methyl-2-pyrrolidinyl)pyridine. Itsempirical formula is C₁₀H₁₄N₂, and its structural formula is

Nicotine may be isolated and purified from nature or syntheticallyproduced in any manner. This term “nicotine” is also intended toencompass the commonly occurring salts containing pharmacologicallyacceptable anions, such as hydrochloride, hydrobromide, hydroiodide,nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate,lactate, citrate or acid citrate, tartrate or bitartrate, succinate,maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate,ethanesulfonate, benzenesulfonate, p-toluene sulfonate, camphorate andpamoate salts. Nicotine is a colorless to pale yellow, stronglyalkaline, oily, volatile, hygroscopic liquid having a molecular weightof 162.23

Unless specifically indicated otherwise, the term “nicotine” furtherincludes any pharmacologically acceptable derivative or metabolite ofnicotine which exhibits pharmacotherapeutic properties similar tonicotine. Such derivatives, metabolites, and derivatives of metabolitesare known in the art, and include, but are not necessarily limited to,cotinine, norcotinine, nornicotine, nicotine N-oxide, cotinine N-oxide,3-hydroxycotinine and 5-hydroxycotinine or pharmaceutically acceptablesalts thereof. A number of useful derivatives of nicotine are disclosedwithin the Physician's Desk Reference (most recent edition) as well asHarrison's Principles of Internal Medicine. Methods for production ofnicotine derivatives and analogues are well known in the art. See, e.g.,U.S. Pat. Nos. 4,590,278; 4,321,387; 4,452,984; 4,442,292; and4,332,945.

The compounds of the present invention may have asymmetric carbon atoms.All isomers, including diastereomeric mixtures such as racemic mixturesand pure enantiomers are considered as part of the invention.

Without being limited to any one theory, one mechanism of action can bethat after a prolong exposure to nicotinic receptor agonist nicotinicreceptors become desensitized and the nicotinic receptor agonists startworking as nicotinic receptor antagonists. In some embodiments, thenicotinic receptor agonists work as antagonists to reduce or eliminate aside effect induced by a dopaminergic agent.

In some embodiments, the invention provides a composition foradministration of nicotine to an animal. In some embodiments, theinvention provides a composition for administration of nicotine to ananimal to reduce a side effect of a dopaminergic agent, e.g., for theoral delivery of nicotine, that contain at least about 1, 5, 10, 20, 30,40, 50, 60, 70, 80, 90, 95, 99, 99.5, 99.9, or 99.99% nicotine. In someembodiments, the invention provides a composition for the oral deliveryof nicotine that contains no more than about 2, 5, 10, 20, 30, 40, 50,60, 70, 80, 90, 95, 99, 99.5, 99.9, 99.99, or 100% nicotine. In someembodiments, the invention provides a composition that contains about1-100% nicotine, or about 10-100% nicotine, or about 20-100% nicotine,or about 50-100% nicotine, or about 80-100% nicotine, or about 90-100%nicotine, or about 95-100% nicotine, or about 99-100% nicotine. In someembodiments, the invention provides a composition that contains about1-90% nicotine, or about 10-90% nicotine, or about 20-90% nicotine, orabout 50-90% nicotine, or about 80-90% nicotine. In some embodiments,the invention provides a composition that contains about 1-75% nicotine,or about 10-75% nicotine, or about 20-75% nicotine, or about 50-75%nicotine. In some embodiments, the invention provides a composition thatcontains about 1-50% nicotine, or about 10-50% nicotine, or about 20-50%nicotine, or about 30-50% nicotine, or about 40-50% nicotine. In someembodiments, the invention provides a composition that contains about1-40% nicotine, or about 10-40% nicotine, or about 20-40% nicotine, orabout 30-40% nicotine. In some embodiments, the invention provides acomposition that contains about 1-30% nicotine, or about 10-30%nicotine, or about 20-30% nicotine. In some embodiments, the inventionprovides a composition that contains about 1-20% nicotine, or about10-20% nicotine. In some embodiments, the invention provides acomposition that contains about 1-10% nicotine. In some embodiments, theinvention provides a composition that contains about 1, 2, 5, 10, 20,30, 40, 50, 60, 70, 80, 90, 95, 96, 97, 98, or 99% nicotine.

In some of these embodiments, a pharmaceutically acceptable excipient isalso included.

Dopaminergic Agents

In one aspect, the invention provides compositions and methods to reduceor eliminate the effects of a dopaminergic agent. In some embodiments,the compositions and methods retain or enhance a desired effect of thedopaminergic agent, e.g., antiparkinsonian effect. The methods andcompositions of the invention apply to any dopaminergic agent for whichit is desired to reduce one or more side effects. In some embodiments,the compositions and methods of the invention utilize a dopamineprecursor. In some embodiments, the compositions and methods of theinvention utilize a dopamine agonist. In some embodiments, thedopaminergic agent is levodopa, bromocriptine, pergolide, pramipexole,cabergoline, ropinorole, apomorphine or a combination thereof. In someembodiments, the dopaminergic agent is levodopa. In some embodiments,the compositions and methods of the invention utilize one or more agentsused in the art in combination with a dopamine agent treatment toachieve a therapeutic effect. For instance, in one exemplary embodimentthe compositions and methods of the invention utilize levodopa incombination with an agent such as carbidopa, which blocks the conversionof levodopa to dopamine in the blood. In another exemplary embodiment,the compositions and methods of the invention utilize levodopa incombination with a COMT Inhibitor, such as entacapone. In anotherexemplary embodiment, the compositions and methods of the inventionutilize levodopa in combination with a monoamine oxidase type B (MAO-B)inhibitor such as selegiline. In yet another exemplary embodiment, thecompositions and methods of the invention utilize levodopa incombination with amantadine.

Levodopa

Levodopa, an aromatic amino acid, is a white, crystalline compound,slightly soluble in water, with a molecular weight of 197.2. It isdesignated chemically as (−)-L-a-amino-b-(3,4-dihydroxybenzene)propanoicacid. Its empirical formula is C₉H₁₁NO₄, and its structural formula is

Levodopa is used for the treatment of Parkinson's disease. Parkinson'sdisease is a progressive, neurodegenerative disorder of theextrapyramidal nervous system affecting the mobility and control of theskeletal muscular system. Its characteristic features include restingtremor, rigidity, and bradykinetic movements

Current evidence indicates that symptoms of Parkinson's disease arerelated to depletion of dopamine in the corpus striatum. Administrationof dopamine is ineffective in the treatment of Parkinson's diseaseapparently because it does not cross the blood-brain barrier. However,levodopa, the metabolic precursor of dopamine, does cross theblood-brain barrier, and presumably is converted to dopamine in thebrain. This is thought to be the mechanism whereby levodopa relievessymptoms of Parkinson's disease.

However, although initially very effective, long-term treatment withlevodopa gives rise to multiple complications. Levodopa treatment maycause nausea, vomiting, involuntary movements (e.g. dyskinesias), mentaldisturbances, depression, syncope, and hallucinations. The precisepathophysiological mechanisms of levodopa side effects are stillenigmatic, but are thought to be due to increased brain dopaminefollowing administration of levodopa.

Previous work has shown that levodopa induced-dyskinesias (LIDs) arisedue to enhanced intermittent stimulation of D1, D2 and/or other dopaminereceptor subtypes. This results in an imbalance in activity of the twomajor striatal output pathways, possibly through activation of D1 andinhibition of D2 receptors on the direct and indirect dopaminergicpathways, respectively, although there is some overlap between striatalefferents. Recent data suggest that D1 receptors, through enhancedG-protein coupling, may play a more prominent role in functionalhypersensitivity associated with levodopa-induced dyskinesias, while D2receptor activation may be more closely linked to the antiparkinsonianaction of dopaminergic drugs

Side Effects

The principal adverse reactions of dopaminergic agent include headache,diarrhea, hypertension, nausea, vomiting, involuntary movements (e.g.dyskinesias), mental disturbances, depression, syncope, hallucinations,and abnormal renal function.

The invention provides compositions and methods utilizing a nicotinicreceptor modulator that reduces or eliminates a side effect associatedwith dopaminergic agent treatment. In some embodiments, the inventionprovides compositions and methods utilizing a nicotinic receptormodulator that reduces or eliminates dyskinesias associated withdopaminergic agent treatment. Without being limited to any theory, onepossibility is that nicotinic receptor modulator exerts its effect byacting at nicotinic acetylcholine receptors (nAChR), which are expressedin the striatum. There is a dense cholinergic innervation in striatumthat closely coincides with dopaminergic neurons. Under physiologicalconditions, these cholinergic interneurons tonically releaseacetylcholine, which stimulates nicotinic receptors on dopaminergicnerve terminals to release dopamine. Similarly, exogenously appliedagents such as nicotine result in a release of dopamine from striatalterminals.

In some embodiments, the invention provides compositions and methodsutilizing a combination of a dopaminergic agent and a nicotinic receptormodulator that reduces or eliminates a side effect associated withdopaminergic agent treatment. Typically, the nicotinic receptormodulator is an agonist. In some embodiments, the nicotinic receptoragonist modulates a nicotinic receptor comprising at least one

subunit or a nicotinic receptor containing at least one

subunit and at least one β subunit. In some embodiments, the α subunitis selected from the group consisting of α2, α3, α4, α5, α6, α7, α8, α9,and α10 and the β subunit is selected from the group consisting of β2,β3 and β4. In some embodiments, the nicotinic receptor agonist modulatesa nicotinic receptor composed of subunits selected from the groupconsisting of α4β2, α6β2, α4α6β2, α4α5β2 α4α6β2β3, α6β2β3 and α4α2β2. Insome embodiments, the nicotinic receptor modulator modulates a nicotinicreceptor comprising at least one α subunit selected from the groupconsisting of α4, α6, and α7.

In some embodiments, the dopaminergic agents include a dopamineprecursor or a dopamine receptor agonist Examples of dopaminergic agentsinclude, but are not limited to, levodopa, bromocriptine, pergolide,pramipexole, cabergoline, ropinorole, apomorphine or a combinationthereof.

The nicotinic receptor modulator causing a decrease in the side effectsof the dopaminergic agent may be an agonist or an antagonist of aprotein. The modulatory effect may be dose-dependent, e.g., somemodulators act as agonists in one dosage range and antagonists inanother. In some embodiments, a modulator of a nicotinic receptor isused in a dosage wherein it acts primarily as an agonist.

Typically, the use of the nicotinic receptor modulator, e.g., agonist,results in a decrease in one or more side effects of the dopaminergicagent. The therapeutic effect(s) of the dopaminergic agent may bedecreased, remain the same, or increase; however, in preferredembodiments, if the therapeutic effect is decreased, it is not decreasedto the same degree as the side effects. It will be appreciated that agiven dopaminergic agent may have more than one therapeutic effects andor one or more side effects, and it is possible that the therapeuticratio (in this case, the ratio of change in desired effect to change inundesired effect) may vary depending on which effect is measured.However, at least one therapeutic effect of the dopaminergic agent isdecreased to a lesser degree than at least one side effect of thedopaminergic agent.

In addition, in some embodiments, one or more therapeutic effects of thedopaminergic agent are enhanced by use in combination with a nicotinicreceptor modulator, while one or more side effects of the dopaminergicagent is reduced or substantially eliminated. For example, in someembodiments, the antiparkinsonian effect of the dopaminergic agent isenhanced while one or more side effects of the dopaminergic agent isreduced or substantially eliminated.

Hence, in some embodiments the invention provides compositions thatinclude a dopaminergic agent and a nicotinic receptor modulator, wherethe dopaminergic agent is present in an amount sufficient to exert atherapeutic effect and the nicotinic receptor modulator is present in anamount sufficient to decrease side effect of the dopaminergic agent whencompared to the side effect without the nicotinic receptor modulator,when the composition is administered to an animal.

In some embodiments, compositions of the invention include one or moredopaminergic agent with one or more nicotinic receptor modulators. Oneor more of the dopaminergic agent may have one or more side effectswhich are desired to be decreased. In some embodiments, compositions ofthe invention include one or more agents, one or more dopaminergic agentwith one or more nicotinic receptor modulators. The one or more agentsare agents used in the art in combination with a dopamine agenttreatment to achieve a therapeutic effect and/or reduce a side effect.In some embodiments, the compositions of the invention include an agentsuch as carbidopa, which blocks the conversion of levodopa to dopaminein the blood. In some embodiments, the compositions of the inventioninclude a COMT Inhibitor, such as entacapone. In some embodiments, thecompositions of the invention include a monoamine oxidase type B (MAO-B)inhibitor such as selegiline. In some embodiments, the compositions ofthe invention include amantadine.

Compositions of the invention may be prepared in any suitable form foradministration to an animal. In some embodiments, the invention providespharmaceutical compositions.

In some embodiments, the invention provides compositions suitable fororal administration. In some embodiments, compositions are suitable fortransdermal administration. In some embodiments, compositions aresuitable for injection by any standard route of injection, e.g.,intravenous, subcutaneous, intramuscular, or intraperitoneal.Compositions suitable for other routes of administration, such andinhalation, are also encompassed by the invention, as described herein.

In some embodiments the invention provides methods of decreasing a sideeffect of a dopaminergic agent in an animal, e.g. a human, that hasreceived an amount of the dopaminergic agent sufficient to produce aside effect by administering to the animal, e.g., human, an amount of anicotinic receptor modulator sufficient to reduce or eliminate the sideeffect.

The side effect may be acute or chronic. The effect may be biochemical,cellular, at the tissue level, at the organ level, at the multi-organlevel, or at the level of the entire organism. The effect may manifestin one or more objective or subjective manners, any of which may be usedto measure the effect. If an effect is measured objectively orsubjectively (e.g., dyskinesias and the like), any suitable method forevaluation of objective or subjective effect may be used. Examplesinclude visual and numeric scales and the like for evaluation by anindividual. A further example includes sleep latency for measurement ofdrowsiness, or standard tests for measurement of concentration,mentation, memory, and the like. These and other methods of objectiveand subjective evaluation of side effects by an objective observer, theindividual, or both, are well-known in the art.

A “therapeutic effect,” as that term is used herein, encompasses atherapeutic benefit and/or a prophylactic benefit. By therapeuticbenefit is meant eradication or amelioration of the underlying disorderbeing treated. Also, a therapeutic benefit is achieved with theeradication or amelioration of one or more of the physiological symptomsassociated with the underlying disorder such that an improvement isobserved in the patient, notwithstanding that the patient may still beafflicted with the underlying disorder. For prophylactic benefit, thecompositions may be administered to a patient at risk of developing aparticular disease, or to a patient reporting one or more of thephysiological symptoms of a disease, even though a diagnosis of thisdisease may not have been made. A prophylactic effect includes delayingor eliminating the appearance of a disease or condition, delaying oreliminating the onset of symptoms of a disease or condition, slowing,halting, or reversing the progression of a disease or condition, or anycombination thereof.

Compositions

In one aspect the invention provides compositions that include anicotinic receptor modulator, e.g., that reduces or eliminates a sideeffect of one or more dopaminergic agent. In some embodiments, adopaminergic agent is co-administered with the nicotinic receptormodulator. “Co-administration,” “administered in combination with,” andtheir grammatical equivalents, as used herein, encompassesadministration of two or more agents to an animal so that both agentsand/or their metabolites are present in the animal at the same time.Co-administration includes simultaneous administration in separatecompositions, administration at different times in separatecompositions, or administration in a composition in which both agentsare present.

In some embodiments, the invention provides compositions containing anicotinic receptor modulator. In further embodiments the inventionprovides pharmaceutical compositions that further include apharmaceutically acceptable excipient.

In some embodiments, the invention includes pharmaceutical compositionswherein the nicotinic receptor modulator is present in an amountsufficient to decrease a side effect of a dopaminergic agent when thecomposition is administered to an animal. In some embodiments, theinvention includes pharmaceutical compositions where the nicotinicreceptor modulator is present in an amount sufficient to decrease a sideeffect of a dopaminergic agent and to prevent addiction to the nicotinicreceptor modulator when the composition is administered to an animal.For example, the pharmaceutical compositions including a nicotinicreceptor modulator are administered through various routes of deliveryfurther described herein.

In one embodiment, the pharmaceutical compositions including a nicotinicreceptor modulator are administered orally to an animal. In variousembodiments, the invention provides a solid pharmaceutical compositionfor oral administration containing an effective amount of a nicotinicreceptor modulator and a pharmaceutical excipient suitable for oraladministration; or a liquid pharmaceutical composition for oraladministration containing an effective amount of a nicotinic receptormodulator and a pharmaceutical excipient suitable for oraladministration.

In some embodiments, the pharmaceutical compositions are suitable fortransdermal administration.

In some embodiments, the invention provides a composition containing anicotinic receptor modulator, where nicotinic receptor modulator ispresent in an amount sufficient to decrease a side effect of adopaminergic agent by a measurable amount, compared to the side effectwithout the nicotinic receptor modulator, when the composition isadministered to an animal. In some embodiments, a side effect of thedopaminergic agent is decreased by an average of at least about 5, 10,15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, ormore than 95%, compared to the side effect without the nicotinicreceptor modulator. In some embodiments, a side effect of thedopaminergic agent is decreased by an average of at least about 5%,compared to the side effect without the nicotinic receptor modulator. Insome embodiments, a side effect of the dopaminergic agent is decreasedby an average of at least about 10%, compared to the side effect withoutthe nicotinic receptor modulator. In some embodiments, a side effect ofthe dopaminergic agent is decreased by an average of at least about 15%,compared to the side effect without the nicotinic receptor modulator. Insome embodiments, a side effect of the dopaminergic agent is decreasedby an average of at least about 20%, compared to the side effect withoutthe nicotinic receptor modulator. In some embodiments, a side effect ofthe dopaminergic agent is decreased by an average of at least about 30%,compared to the side effect without the nicotinic receptor modulator. Insome embodiments, a side effect is substantially eliminated compared tothe side effect without the nicotinic receptor modulator. “Substantiallyeliminated” as used herein encompasses no measurable or no statisticallysignificant side effect (one or more side effects) of the dopaminergicagent, when a nicotinic receptor modulator is administered.

In some embodiments, the invention provides compositions that contain anicotinic receptor agonist, e.g., nicotine, where the nicotinic receptoragonist, e.g., nicotine is present in an amount sufficient to decrease aside effect of the dopaminergic agent by a measurable amount, comparedto the side effect without the nicotinic receptor agonist, e.g.,nicotine when the composition is administered to an animal. Themeasurable amount may be an average of at least about 5%, 10%, 15%, 20%,30% or more than 30% as described herein. The side effect may be anyside effect as described herein. In some embodiments, the side effect isdyskinesias.

In exemplary embodiments, the invention provides a composition thatcontains nicotine, where nicotine is present in an amount effective todecrease a side effect of a dopaminergic agent by a measurable amount(e.g., an average of at least about 5, 10, 15, 20, 30 or more than 30%,as described herein). In some exemplary embodiments, the inventionprovides a composition that contains nicotine, where nicotine is presentin an amount effective to decrease a side effect of a dopaminergic agentby a measurable amount (e.g., an average of at least about 5, 10, 15,20, or more than 20%, as described herein) and to increase thetherapeutic effect of the dopaminergic agent by a measurable amount(e.g., an average of at least about 5, 10, 15, 20, 30 or more than 30%,as described herein). In some embodiments, the invention provides acomposition that contains nicotine, where nicotine is present in amounteffective to decrease a side effect of a dopaminergic agent by ameasurable amount (e.g., an average of at least about 5, 10, 15, 20, 30or more than 30%, as described herein) and to prevent addition tonicotine. In some exemplary embodiments, the invention provides acomposition that contains nicotine, where nicotine is present in anamount effective to decrease a side effect of a dopaminergic agent by ameasurable amount (e.g., an average of at least about 5, 10, 15, 20, 30or more than 30%, as described herein), and to increase the therapeuticeffect of the dopaminergic agent by a measurable amount (e.g., anaverage of at least about 5, 10, 15, 20, 30 or more than 30%, asdescribed herein), and to prevent addiction to nicotine. The side effectmay be any side effect as described herein. In some embodiments, theside effect is dyskinesias.

In some embodiments, the invention provides compositions containing acombination of a dopaminergic agent and a nicotinic receptor modulatorthat reduces or eliminates a side effect of the dopaminergic agent. Insome embodiments, the invention provides compositions containing acombination of a dopaminergic agent and a nicotinic receptor modulatorthat reduces or eliminates a side effect of the dopaminergic agent,where the nicotine receptor modulator is present in an amount thatprevents addiction to the nicotine receptor modulator. In someembodiments, the invention provides pharmaceutical compositions thatfurther include a pharmaceutically acceptable excipient. In someembodiments, the pharmaceutical compositions are suitable for oraladministration. In some embodiments, the pharmaceutical compositions aresuitable for transdermal administration. In some embodiments, thepharmaceutical compositions are suitable for injection. Other forms ofadministration are also compatible with embodiments of thepharmaceutical compositions of the invention, as described herein.

In some embodiments, the nicotinic receptor modulator comprises anagonist or antagonist as described herein. In some embodiments, afterprolong exposure to an agonist the nicotinic receptors becomedesensitized and the nicotinic receptor agonists described herein workas antagonists.

In some embodiments, the side effect of the dopaminergic agent that isreduced is selected from the group consisting of involuntary movements(e.g. dyskinesias), mental disturbances, depression, syncope,hallucinations, or combinations thereof. In some embodiments, the sideeffect of the dopaminergic agent that is reduced is dyskinesias.

In some embodiments the dopaminergic agent is a dopamine precursor or adopamine agonist. Examples of dopaminergic agents include, but are notlimited to, levodopa, bromocriptine, pergolide, pramipexole,cabergoline, ropinorole, apomorphine or a combination thereof

In some embodiments, compositions of the invention include one or moreagents, one or more dopaminergic agent with one or more nicotinicreceptor modulators. The one or more agents are agents used in the artin combination with a dopamine agent treatment to achieve a therapeuticeffect and/or reduce a side effect. In some embodiments, thecompositions of the invention include an agent such as carbidopa, whichblocks the conversion of levodopa to dopamine in the blood. In someembodiments, the compositions of the invention include a COMT Inhibitor,such as entacapone. In some embodiments, the compositions of theinvention include a monoamine oxidase type B (MAO-B) inhibitor such asselegiline. In some embodiments, the compositions of the inventioninclude amantadine.

In some embodiments, the invention provides a composition containing adopaminergic agent and a nicotinic receptor modulator, where thedopaminergic agent is present in an amount sufficient to exert atherapeutic effect and the nicotinic receptor modulator is present in anamount sufficient to decrease side effect of the dopaminergic agent by ameasurable amount, compared to the side effect without the nicotinicreceptor modulator, when the composition is administered to an animal.In some embodiments, a side effect of the dopaminergic agent isdecreased by an average of at least about 5, 10, 15, 20, 25, 30, 35, 40,45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or more than 95%, comparedto the side effect without the nicotinic receptor modulator. In someembodiments, a side effect of the dopaminergic agent is decreased by anaverage of at least about 5%, compared to the side effect without thenicotinic receptor modulator. In some embodiments, a side effect of thedopaminergic agent is decreased by an average of at least about 10%,compared to the side effect without the nicotinic receptor modulator. Insome embodiments, a side effect of the dopaminergic agent is decreasedby an average of at least about 15%, compared to the side effect withoutthe nicotinic receptor modulator. In some embodiments, a side effect ofthe dopaminergic agent is decreased by an average of at least about 20%,compared to the side effect without the nicotinic receptor modulator. Insome embodiments, a side effect of the dopaminergic agent is decreasedby an average of at least about 30%, compared to the side effect withoutthe nicotinic receptor modulator. In some embodiments, a side effect issubstantially eliminated compared to the side effect without thenicotinic receptor modulator. “Substantially eliminated” as used hereinencompasses no measurable or no statistically significant side effect(one or more side effects) of the dopaminergic agent, when administeredin combination with the nicotinic receptor modulator.

Thus, in some embodiments, the invention provides compositions thatcontain a nicotinic receptor agonist, e.g., nicotine, and a dopaminergicagent, where the dopaminergic agent is present in an amount sufficientto exert an therapeutic effect and the nicotinic receptor agonist, e.g.,nicotine is present in an amount sufficient to decrease a side effect ofthe dopaminergic agent by a measurable amount, compared to the sideeffect without the nicotinic receptor agonist, e.g., nicotine when thecomposition is administered to an animal. The measurable amount may bean average of at least about 5%, 10%, 15%, 20%, 30% or more than 30% asdescribed herein. The side effect may be any side effect as describedherein. In some embodiments, the side effect is dyskinesias.

In some embodiments, the invention provides compositions that contain anicotinic receptor agonist that is nicotine, and a dopaminergic agentthat is levodopa, where the levodopa is present in an amount sufficientto exert a therapeutic effect and nicotine is present in an amountsufficient to decrease side effect of levodopa by a measurable amount,compared to the side effect without nicotine when the composition isadministered to an animal. The measurable amount may be an average of atleast about 5%, 10%, 15%, 20%, 30% or more than 30% as described herein.The side effect may be any side effect as described herein. In someembodiments, the side effect is dyskinesias.

In some embodiments, the nicotinic receptor modulator is present in anamount sufficient to decrease a side effect of the dopaminergic agent bya measurable amount and to increase a therapeutic effect of thedopaminergic agent by a measurable amount, compared to the side effectand therapeutic effect without the nicotinic receptor modulator, whenthe composition is administered to an animal. In some embodiments, atherapeutic effect of the dopaminergic agent is increased by an averageof at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70,75, 80, 85, 90, 95, or more than 95%, compared to the therapeutic effectwithout the nicotinic receptor modulator. In some embodiments, atherapeutic effect of the dopaminergic agent is increased by an averageof at least about 5%, compared to the therapeutic effect without thenicotinic receptor modulator. In some embodiments, a therapeutic effectof the dopaminergic agent is increased by an average of at least about10%, compared to the therapeutic effect without the nicotinic receptormodulator. In some embodiments, a therapeutic effect of the dopaminergicagent is increased by an average of at least about 15%, compared to thetherapeutic effect without the nicotinic receptor modulator. In someembodiments, a therapeutic effect of the dopaminergic agent is increasedby an average of at least about 20%, compared to the therapeutic effectwithout the nicotinic receptor modulator. In some embodiments, atherapeutic effect of the dopaminergic agent is increased by an averageof at least about 30%, compared to the therapeutic effect without thenicotinic receptor modulator. In some embodiments, a therapeutic effectof the dopaminergic agent is increased by an average of at least about40%, compared to the therapeutic effect without the nicotinic receptormodulator. In some embodiments, a therapeutic effect of the dopaminergicagent is increased by an average of at least about 50%, compared to thetherapeutic effect without the nicotinic receptor modulator.

Thus, in some embodiments, the invention provides compositionscontaining a nicotinic receptor modulator present in an amountsufficient to decrease a side effect of a dopaminergic agent by anaverage of at least about 5% and to increase a therapeutic effect of thedopaminergic agent by an average of at least about 5%, compared to theside effect and therapeutic effect without the nicotinic receptormodulator, when the composition is administered to an animal incombination with the dopaminergic agent. In some embodiments, theinvention provides compositions containing a nicotinic receptormodulator present in an amount sufficient to decrease a side effect of adopaminergic agent by an average of at least about 10% and to increase atherapeutic effect of the dopaminergic agent by an average of at leastabout 10%, compared to the side effect and therapeutic effect withoutthe nicotinic receptor modulator, when the composition is administeredto an animal in combination with the dopaminergic agent. In someembodiments, the invention provides compositions containing a nicotinicreceptor modulator present in an amount sufficient to decrease a sideeffect of a dopaminergic agent by an average of at least about 20% andto increase a therapeutic effect of the dopaminergic agent by an averageof at least about 20%, compared to the side effect and therapeuticeffect without the nicotinic receptor modulator, when the composition isadministered to an animal in combination with the dopaminergic agent. Insome embodiments, the invention provides compositions containing anicotinic receptor modulator present in an amount sufficient to decreasea side effect of a dopaminergic agent by an average of at least about10% and to increase a therapeutic effect of the dopaminergic agent by anaverage of at least about 20%, compared to the side effect andtherapeutic effect without the nicotinic receptor modulator, when thecomposition is administered to an animal in combination with thedopaminergic agent. In some embodiments, the invention providescompositions containing a nicotinic receptor modulator present in anamount sufficient to decrease a side effect of a dopaminergic agent byan average of at least about 10% and to increase a therapeutic effect ofthe dopaminergic agent by an average of at least about 30%, compared tothe side effect and therapeutic effect without the nicotinic receptormodulator, when the composition is administered to an animal incombination with the dopaminergic agent. In some embodiments, theinvention provides compositions containing a nicotinic receptormodulator present in an amount sufficient to decrease a side effect of adopaminergic agent by an average of at least about 10% and to increase atherapeutic effect of the dopaminergic agent by an average of at leastabout 40%, compared to the side effect and therapeutic effect withoutthe nicotinic receptor modulator, when the composition is administeredto an animal in combination with the dopaminergic agent. In someembodiments, the invention provides compositions containing a nicotinicreceptor modulator present in an amount sufficient to decrease a sideeffect of a dopaminergic agent by an average of at least about 10% andto increase a therapeutic effect of the dopaminergic agent by an averageof at least about 50%, compared to the side effect and therapeuticeffect without the nicotinic receptor modulator, when the composition isadministered to an animal in combination with the dopaminergic agent.

In some embodiments, the invention provides compositions containing anicotinic receptor agonist, e.g., nicotine, present in an amountsufficient to decrease a side effect of a dopaminergic agent by anaverage of at least about 5% and to increase a therapeutic effect of thedopaminergic agent by an average of at least about 5%, when thecomposition is administered to an animal in combination with thedopaminergic agent, compared to the side effect and therapeutic effectwithout the nicotinic receptor agonist, e.g., nicotine. In someembodiments, the invention provides compositions containing a nicotinicreceptor agonist, e.g., nicotine present in an amount sufficient todecrease a side effect of a dopaminergic agent by an average of at leastabout 10% and to increase a therapeutic effect of the dopaminergic agentby an average of at least about 10%, when the composition isadministered to an animal in combination with the dopaminergic agent,compared to the side effect and therapeutic effect when the dopaminergicagent is administered without the a nicotinic receptor agonist, e.g.,nicotine. In some embodiments, the invention provides compositionscontaining a nicotinic receptor agonist, e.g., nicotine present in anamount sufficient to decrease a side effect of a dopaminergic agent byan average of at least about 20% and to increase a therapeutic effect ofthe dopaminergic agent by an average of at least about 20%, when thecomposition is administered to an animal in combination with thedopaminergic agent, compared to the side effect and therapeutic effectwhen the dopaminergic agent is administered without the a nicotinicreceptor agonist, e.g., nicotine. In some embodiments, the inventionprovides compositions containing a nicotinic receptor agonist, e.g.,nicotine present in an amount sufficient to decrease a side effect of adopaminergic agent by an average of at least about 10% and to increase atherapeutic effect of the dopaminergic agent by an average of at leastabout 20%, when the composition is administered to an animal incombination with the dopaminergic agent, compared to the side effect andtherapeutic effect when the dopaminergic agent is administered withoutthe a nicotinic receptor agonist, e.g., nicotine. In some embodiments,the invention provides compositions containing a nicotinic receptoragonist, e.g., nicotine present in an amount sufficient to decrease aside effect of a dopaminergic agent by an average of at least about 10%and to increase a therapeutic effect of the dopaminergic agent by anaverage of at least about 30%, when the composition is administered toan animal in combination with the dopaminergic agent, compared to theside effect and therapeutic effect when the dopaminergic agent isadministered without the nicotinic receptor agonist, e.g., nicotine. Insome embodiments, the invention provides compositions containing anicotinic receptor agonist, e.g., nicotine present in an amountsufficient to decrease a side effect of a dopaminergic agent by anaverage of at least about 10% and to increase a therapeutic effect ofthe dopaminergic agent by an average of at least about 40%, when thecomposition is administered to an animal in combination with thedopaminergic agent, compared to the side effect and therapeutic effectwhen the dopaminergic agent is administered without the nicotinicreceptor agonist, e.g., nicotine. In some embodiments, the inventionprovides compositions containing a nicotinic receptor agonist, e.g.,nicotine present in an amount sufficient to decrease a side effect of adopaminergic agent by an average of at least about 10% and to increase atherapeutic effect of the dopaminergic agent by an average of at leastabout 50%, when the composition is administered to an animal incombination with the dopaminergic agent, compared to the side effect andtherapeutic effect when the dopaminergic agent is administered withoutthe a nicotinic receptor agonist, e.g., nicotine.

In exemplary embodiments, the invention provides a composition thatcontains nicotine and a dopaminergic agent, such as levodopa or adopamine agonist, where the dopaminergic agent is present in an amountsufficient to exert a therapeutic effect, and nicotine is present in anamount effective to decrease a side effect of the dopaminergic agent bya measurable amount (e.g., an average of at least about 5, 10, 15, 20,30 or more than 30%, as described herein) and to increase thetherapeutic effect of the dopaminergic agent by a measurable amount(e.g., an average of at least about 5, 10, 15, 20, 30 or more than 30%,as described herein). The side effect may be any side effect asdescribed herein. In some embodiments, the side effect is dyskinesias.

An “average” as used herein is preferably calculated in a set of normalhuman subjects, this set being at least about 3 human subjects,preferably at least about 5 human subjects, preferably at least about 10human subjects, even more preferably at least about 25 human subjects,and most preferably at least about 50 human subjects.

In some embodiments, the invention provides a composition that containsa dopaminergic agent and a nicotinic receptor modulator, e.g. an agonistsuch as nicotine. In some embodiments, the a concentration of one ormore of the dopaminergic agents and/or nicotinic receptor modulator,e.g. an agonist such as a nicotine is less than 100%, 90%, 80%, 70%,60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%,10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%,0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%,0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%,0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or0.0001% w/w, w/v or v/v.

In some embodiments, a concentration of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. an agonist such as anicotine is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%,19.50%, 19.25% 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25%17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%,14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25%12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%,9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%,6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%,3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%,0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%,0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%,0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%,0.0003%, 0.0002%, or 0.0001% w/w, w/v, or v/v.

In some embodiments, a concentration of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. an agonist such as anicotine is in the range from approximately 0.0001% to approximately50%, approximately 0.001% to approximately 40%, approximately 0.01% toapproximately 30%, approximately 0.02% to approximately 29%,approximately 0.03% to approximately 28%, approximately 0.04% toapproximately 27%, approximately 0.05% to approximately 26%,approximately 0.06% to approximately 25%, approximately 0.07% toapproximately 24%, approximately 0.08% to approximately 23%,approximately 0.09% to approximately 22%, approximately 0.1% toapproximately 21%, approximately 0.2% to approximately 20%,approximately 0.3% to approximately 19%, approximately 0.4% toapproximately 18%, approximately 0.5% to approximately 17%,approximately 0.6% to approximately 16%, approximately 0.7% toapproximately 15%, approximately 0.8% to approximately 14%,approximately 0.9% to approximately 12%, approximately 1% toapproximately 10% w/w, w/v or v/v. v/v.

In some embodiments, a concentration of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. a an agonist such as anicotine is in the range from approximately 0.001% to approximately 10%,approximately 0.01% to approximately 5%, approximately 0.02% toapproximately 4.5%, approximately 0.03% to approximately 4%,approximately 0.04% to approximately 3.5%, approximately 0.05% toapproximately 3%, approximately 0.06% to approximately 2.5%,approximately 0.07% to approximately 2%, approximately 0.08% toapproximately 1.5%, approximately 0.09% to approximately 1%,approximately 0.1% to approximately 0.9% w/w, w/v or v/v.

In some embodiments, the amount of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. an agonist such as anicotine is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g,2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g,0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g,0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g,0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g,0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.

In some embodiments, the amount of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. a an agonist such as anicotine is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g,0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g,0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g,0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g,0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g,7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.

In some embodiments, the amount of one or more of the dopaminergicagents and/or nicotinic receptor modulator, e.g. a an agonist such as anicotine is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

In exemplary embodiments, compositions of the invention includenicotine, where nicotine is present in an amount from about 0.1-1000 mg,or about 1-1000 mg, or about 5-1000 mg, or about 10-1000 mg, or about1-500 mg, or about 5-500 mg, or about 50-500 mg, or about 100-500 mg, orabout 200-1000 mg, or about 200-800 mg, or about 200-700 mg, or about0.01 mg, or about 0.1 mg, or about 0.5 mg, or about 1 mg, or about 10mg, or about 25 mg, or about 50 mg, or about 100 mg, or about 200 mg, orabout 250 mg, or about 300 mg, or about 400 mg, or about 500 mg, orabout 600 mg, or about 700 mg, or about 800 mg, or about 900 mg, orabout 1000 mg. In some embodiments, compositions of the inventioninclude nicotine, where nicotine is present in an amount from about0.1-10 mg. In some embodiments, compositions of the invention includenicotine, where nicotine is present in an amount from about 0.1 to about5 mg. In some embodiments, compositions of the invention includenicotine, where nicotine is present in an amount from about 0.1 to about2.8 mg. In some embodiments, compositions of the invention includenicotine, where nicotine is present in an amount that is less than 3 mg.In some embodiments, compositions of the invention include nicotine,where nicotine is present in an amount from about 0.5 mg.

In exemplary embodiments, compositions of the invention include nicotineand levodopa, where nicotine is present in an amount from about 1-1000mg, or about 10-1000 mg, or about 50-1000 mg, or about 100-1000 mg, orabout 1-500 mg, or about 5-500 mg, or about 50-500 mg, or about 100-500mg, or about 200-1000 mg, or about 200-800 mg, or about 200-700 mg, orabout 1 mg, or about 10 mg, or about 25 mg, or about 50 mg, or about 100mg, or about 200 mg, or about 250 mg, or about 300 mg, or about 400 mg,or about 500 mg, or about 600 mg, or about 700 mg, or about 800 mg, orabout 900 mg, or about 1000 mg, and levodopa is present in an amountfrom 0.01 to 1000 mg, or about 0.1-800 mg, or about 0.1, 0.5, 1, 5, 10,20, 50, 80, 100, 150, 200, 300, 400, or 500 mg.

In some embodiments, nicotine/levodopa is present at about 0.1/50 mg(nicotine/levodopa). In some embodiments, nicotine is present at about0.5 mg and levodopa is present at about 50 mg. In some embodiments,nicotine is present at about 0.5 mg and levodopa is present at about 100mg. In some embodiments, nicotine is present at about 0.5 mg andlevodopa is present at about 150 mg. In some embodiments, nicotine ispresent at about 0.5 mg and levodopa is present at about 300 mg. In someembodiments, nicotine is present at about 0.5 mg and levodopa is presentat about 1000 mg. In some embodiments, nicotine is present at about 1 mgand levodopa is present at about 50 mg. In some embodiments, nicotine ispresent at about 1 mg and levodopa is present at about 100 mg. In someembodiments, nicotine is present at about 1 mg and levodopa is presentat about 150 mg. In some embodiments, nicotine is present at about 1 mgand levodopa is present at about 300 mg. In some embodiments, nicotineis present at about 1 mg and levodopa is present at about 1000 mg. Insome embodiments, nicotine is present at about 5 mg and levodopa ispresent at about 50 mg. In some embodiments, nicotine is present atabout 5 mg and levodopa is present at about 100 mg. In some embodiments,nicotine is present at about 5 mg and levodopa is present at about 150mg. In some embodiments, nicotine is present at about 5 mg and levodopais present at about 500 mg. In some embodiments, nicotine is present atabout 1 mg and levodopa is present at about 50 mg.

In some embodiments, nicotine is present at about 0.5 mg and levodopa ispresent at about 100 mg. In some embodiments, nicotine is present atabout 0.5 mg and levodopa is present at about 150 mg. In someembodiments, nicotine is present at about 0.5 mg and levodopa is presentat about 500 mg. In some embodiments, nicotine is present at about 1 mgand levodopa is present at about 100 mg. In some embodiments, nicotineis present at about 1 mg and levodopa is present at about 150 mg. Insome embodiments, nicotine is present at about 1 mg and levodopa ispresent at about 500 mg. In some embodiments, nicotine is present atabout 7 mg and levodopa is present at about 50 mg. In some embodiments,nicotine is present at about 7 mg and levodopa is present at about 100mg. In some embodiments, nicotine is present at about 7 mg and levodopais present at about 150 mg. In some embodiments, nicotine is present atabout 7 mg and levodopa is present at about 500 mg. In some embodiments,nicotine is present at about 10 mg and levodopa is present at about 100mg. In some embodiments, nicotine is present at about 10 mg and levodopais present at about 200 mg. In some embodiments, nicotine is present atabout 10 mg and levodopa is present at about 300 mg. In someembodiments, levodopa is nicotine at about 10 mg and levodopa is presentat about 1000 mg. In some embodiments, nicotine is present at about 14mg and levodopa is present at about 50 mg. In some embodiments, nicotineis present at about 14 mg and levodopa is present at about 100 mg. Insome embodiments, nicotine is present at about 14 mg and levodopa ispresent at about 150 mg. In some embodiments, nicotine is present atabout 14 mg and levodopa is present at about 500 mg. In someembodiments, nicotine is present at about 21 mg and levodopa is presentat about 50 mg. In some embodiments, nicotine is present at about 21 mgand levodopa is present at about 100 mg. In some embodiments, nicotineis present at about 21 mg and levodopa is present at about 150 mg. Insome embodiments, nicotine is present at about 21 mg and levodopa ispresent at about 500 mg. In some embodiments, levodopa is present at anamount that is 100 percent to about 75% of the effective amount whenlevodopa is administered alone.

In another exemplary embodiment, compositions of the invention includenicotine, levodopa and carbidopa. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 25 mg, andcarbidopa is present at about 100 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 25 mg, andcarbidopa is present at about 250 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 12.5 mg, andcarbidopa is present at about 50 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 6.5 mg, andcarbidopa is present at about 25 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 12.5 mg, andcarbidopa is present at about 125 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 6.25 mg, andcarbidopa is present at about 62.5 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 12.5 mg, andcarbidopa is present at about 125 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 100 mg, andcarbidopa is present at about 10 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 100 mg, andcarbidopa is present at about 25 mg. In some embodiments, nicotine ispresent at about 0.5 mg, levodopa is present at about 250 mg, andcarbidopa is present at about 25 mg. In some embodiments, nicotine ispresent at about 1 mg, levodopa is present at about 25 mg, and carbidopais present at about 100 mg. In some embodiments, nicotine is present atabout 1 mg, levodopa is present at about 25 mg, and carbidopa is presentat about 250 mg. In some embodiments, nicotine is present at about 1 mg,levodopa is present at about 12.5 mg, and carbidopa is present at about50 mg. In some embodiments, nicotine is present at about 1 mg, levodopais present at about 6.5 mg, and carbidopa is present at about 25 mg. Insome embodiments, nicotine is present at about 1 mg, levodopa is presentat about 12.5 mg, and carbidopa is present at about 125 mg. In someembodiments, nicotine is present at about 1 mg, levodopa is present atabout 6.25 mg, and carbidopa is present at about 62.5 mg. In someembodiments, nicotine is present at about 1 mg, levodopa is present atabout 100 mg, and carbidopa is present at about 10 mg. In someembodiments, nicotine is present at about 1 mg, levodopa is present atabout 100 mg, and carbidopa is present at about 25 mg. In someembodiments, nicotine is present at about 1 mg, levodopa is present atabout 250 mg, and carbidopa is present at about 25 mg. In someembodiments, nicotine is present at about 4 mg, levodopa is present atabout 25 mg, and carbidopa is present at about 100 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 25 mg, and carbidopa is present at about 250 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 12.5 mg, and carbidopa is present at about 50 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 6.5 mg, and carbidopa is present at about 25 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 12.5 mg, and carbidopa is present at about 125 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 6.25 mg, and carbidopa is present at about 62.5 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 100 mg, and carbidopa is present at about 10 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 100 mg, and carbidopa is present at about 25 mg. In someembodiments, nicotine is present at about 7 mg, levodopa is present atabout 250 mg, and carbidopa is present at about 25 mg.

In liquid preparations, levodopa can be present at about 1-1000 mg/ml,or 1-500 mg/ml, or 1-200 mg/ml, or about 1, 5, 10, 20, 50, 50 or 100mg/ml and nicotine at about 0.001-1000 mg/ml, or about 0.010-1000 mg/ml,or about 0.050-1000 mg/ml, or about 0.1-1000 mg/ml, or about 0.1-500mg/ml, or about 0.05-500 mg/ml, or about 0.010-500 mg/ml, or about0.001-500 mg/ml, or about 1-1000 mg/ml, or about 1-500 mg/ml, or about1-200 mg/ml, or about 0.001 mg/ml, or about 0.025 mg/ml, or about 0.050mg/ml, or about 0.1 mg/ml, or about 0.2 mg/ml, or about 0.25 mg/ml, orabout 0.3 mg/ml, or about 0.4 mg/ml, or about 0.5 mg/ml, or about 0.6mg/ml, or about 0.7 mg/ml, or about 0.8 mg/ml, or about 0.9 mg/ml, orabout 1 mg/ml. At higher levels of nicotine, solubility can be enhancedby adjusting the type of diluent. In some embodiments, levodopa ispresent at an amount that is 100 percent to about 75% of the effectiveamount when levodopa is administered alone.

In some embodiments, a molar ratio of one or more of the dopaminergicagents to the nicotinic receptor modulator, e.g. an agonist such asnicotine can be 0.0001:1 to 1:1. Without limiting the scope of theinvention, the molar ratio of one or more of the dopaminergic agents tothe nicotinic receptor modulator, e.g. an agonist such as nicotine canbe about 0.0001:1 to about 10:1, or about 0.001:1 to about 5:1, or about0.01:1 to about 5:1, or about 0.1:1 to about 2:1, or about 0.2:1 toabout 2:1, or about 0.5:1 to about 2:1, or about 0.1:1 to about 1:1. Insome embodiments, levodopa is present at an amount that is 100 percentto about 75% of the effective amount when levodopa is administeredalone.

Without limiting the scope of the present invention, the molar ratio ofone or more of the dopaminergic agents to the nicotinic receptor agonistcan be about 0.03×10−5:1, 0.1×10−5:1, 0.04×10−3:1, 0.03×10−5:1,0.02×10−5:1, 0.01×10−3:1, 0.1×10−3:1, 0.15×10−3:1, 0.2×10−3:1,0.3×10−3:1, 0.4×10−3:1, 0.5×10−3:1, 0.15×10−2:1, 0.1×10−2:1, 0.2×10−2:1,0.3×10−2:1, 0.4×10−2:1, 0.5×10−2:1, 0.6×10−2:1, 0.8×10−2:1, 0.01:1,0.1:1; or 0.2:1 per dose. In one embodiment, the dopaminergic agent islevodopa. In one embodiment, the nicotinic receptor agonist is nicotine.

Without limiting the scope of the present invention, the molar ratio ofone or more of the dopaminergic agents to the nicotinic receptormodulator, e.g. an agonist such as nicotine can be about 0.001:1,0.002:1, 0.003:1, 0.004:1, 0.005:1, 0.006:1, 0.007:1, 0.008:1, 0.009:1,0.01:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09:1,0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 2:1,3:1, 4:1, or 5:1 per dose. In one embodiment, the dopaminergic agent islevodopa. In one embodiment, the nicotinic receptor agonist is nicotine.

A. Pharmaceutical Compositions

The nicotinic receptor modulators of the invention are usuallyadministered in the form of pharmaceutical compositions. The drugsdescribed above are also administered in the form of pharmaceuticalcompositions. When the nicotinic receptor modulators and the drugs areused in combination, both components may be mixed into a preparation orboth components may be formulated into separate preparations to use themin combination separately or at the same time.

This invention therefore provides pharmaceutical compositions thatcontain, as the active ingredient, a nicotinic receptor modulator or apharmaceutically acceptable salt and/or coordination complex thereof,and one or more pharmaceutically acceptable excipients, carriers,including inert solid diluents and fillers, diluents, including sterileaqueous solution and various organic solvents, permeation enhancers,solubilizers and adjuvants.

This invention further provides pharmaceutical compositions thatcontain, as the active ingredient, a nicotinic receptor modulator or apharmaceutically acceptable salt and/or coordination complex thereof, adopaminergic agent or a pharmaceutically acceptable salt and/orcoordination complex thereof, and one or more pharmaceuticallyacceptable excipients, carriers, including inert solid diluents andfillers, diluents, including sterile aqueous solution and variousorganic solvents, permeation enhancers, solubilizers and adjuvants.

The dopaminergic agent and/or the nicotinic receptor modulator may beprepared into pharmaceutical compositions in dosages as described herein(see, e.g., Compositions). Such compositions are prepared in a mannerwell known in the pharmaceutical art.

Pharmaceutical compositions for oral administration. In someembodiments, the invention provides a pharmaceutical composition fororal administration containing a nicotinic receptor modulator thatreduces or eliminates a side effect of a dopaminergic agent, and apharmaceutical excipient for oral administration. In some embodiments,the invention provides a pharmaceutical composition for oraladministration containing a combination of a dopaminergic agent and anicotinic receptor modulator that reduces or eliminates a side effect ofthe dopaminergic agent, and a pharmaceutical excipient suitable for oraladministration. In some embodiments, the nicotinic receptor modulatorthat reduces or eliminates the side effect of the dopaminergic agent isa nicotinic receptor agonist, e.g. nicotine, as described elsewhereherein. In some embodiments, the nicotinic receptor modulator is presentin amount to prevent addiction to the nicotinic receptor modulator.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing: (i) an effective amountof a nicotinic receptor modulator capable of reducing or eliminating oneor more side effects of the dopaminergic agent; and (ii) apharmaceutical excipient suitable for oral administration. In someembodiments, the nicotinic receptor modulator is present in amount toprevent addiction to the nicotinic receptor modulator.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing: (i) an effective amountof a dopaminergic agent; (ii) an effective amount of a nicotinicreceptor modulator capable of reducing or eliminating one or more sideeffects of the dopaminergic agent; and (iii) a pharmaceutical excipientsuitable for oral administration. In some embodiments, the nicotinicreceptor modulator is present in amount to prevent addiction to thenicotinic receptor modulator.

In some embodiments, the composition further contains: (iv) an effectiveamount of a second dopaminergic agent. In some embodiments, thecomposition further contains: (iv) an effective amount of an agent suchas carbidopa, which blocks the conversion of levodopa to dopamine in theblood. In some embodiments, the composition further contains: (iv) aneffective amount of a COMT Inhibitor, such as entacapone. In someembodiments, the composition further contains: (iv) an effective amountof a monoamine oxidase type B (MAO-B) inhibitor such as selegiline. Insome embodiments, the composition further contains: (iv) an effectiveamount of amantadine.

In some embodiments, the pharmaceutical composition may be a liquidpharmaceutical composition suitable for oral consumption.

In some embodiments, the dopaminergic agent is levodopa. In someembodiments, the dopaminergic agent is a dopamine agonist. In someembodiments, the nicotinic receptor modulator capable of reducing oreliminating one or more side effects of the dopaminergic agent is anicotinic receptor agonist, e.g., nicotine.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing: (i) an effective amountof a nicotinic receptor agonist that is nicotine; and (ii) apharmaceutical excipient suitable for oral administration. In someembodiments, the nicotinic receptor modulator is present in amount toprevent or reduce addiction to the nicotinic receptor modulator.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing: (i) an effective amountof a dopaminergic agent that is levodopa or a dopamine agonist; (ii) aneffective amount of a nicotinic receptor agonist that is nicotine; and(iii) a pharmaceutical excipient suitable for oral administration. Insome embodiments, the nicotinic receptor modulator is present in amountto prevent or reduce addiction to the nicotinic receptor modulator.

In some embodiments, the composition further contains (iv) an effectiveamount of a second dopaminergic agent. In some embodiments, thecomposition further contains: (iv) an effective amount of an agent suchas carbidopa, which blocks the conversion of levodopa to dopamine in theblood. In some embodiments, the composition further contains: (iv) aneffective amount of a COMT Inhibitor, such as entacapone. In someembodiments, the composition further contains: (iv) an effective amountof a monoamine oxidase type B (MAO-B) inhibitor such as selegiline. Insome embodiments, the composition further contains: (iv) an effectiveamount of amantadine.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing an effective amount oflevodopa, an amount of nicotine that is effective in reducing oreliminating a side effect of levodopa, and a pharmaceutically acceptableexcipient. In some embodiments, the invention provides a liquidpharmaceutical composition for oral administration containing aneffective amount of levodopa, an amount of nicotine that is effective inreducing or eliminating a side effect of levodopa, and apharmaceutically acceptable excipient. In some embodiments, nicotine ispresent in amount to prevent or reduce addiction to nicotine.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing levodopa at about 40-800mg, nicotine at about 0.01-200 mg and a pharmaceutically acceptableexcipient. In some embodiments, the invention provides a solidpharmaceutical composition for oral administration containing levodopaat about 40-800 mg, nicotine at about 0.1-10 mg and a pharmaceuticallyacceptable excipient. In some embodiments, the invention provides aliquid pharmaceutical composition for oral administration containinglevodopa at about 0.1-800 mg/ml, nicotine at about 0.005-100 mg/ml and apharmaceutically acceptable excipient.

In some embodiments, the invention provides a solid pharmaceuticalcomposition for oral administration containing an effective amount oflevodopa, an effective amount of nicotine, and a pharmaceuticallyacceptable excipient, wherein the release of nicotine from saidpharmaceutical composition reduces or eliminates a side effect oflevodopa. In some embodiments, the invention provides a liquidpharmaceutical composition for oral administration containing aneffective amount of levodopa, an effective amount of nicotine, and apharmaceutically acceptable excipient, wherein the release of nicotinefrom said pharmaceutical composition reduces or eliminates a side effectof levodopa.

Pharmaceutical compositions of the invention suitable for oraladministration can be presented as discrete dosage forms, such ascapsules, cachets, or tablets, or liquids or aerosol sprays eachcontaining a predetermined amount of an active ingredient as a powder orin granules, a solution, or a suspension in an aqueous or non-aqueousliquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.Such dosage forms can be prepared by any of the methods of pharmacy, butall methods include the step of bringing the active ingredient intoassociation with the carrier, which constitutes one or more necessaryingredients. In general, the compositions are prepared by uniformly andintimately admixing the active ingredient with liquid carriers or finelydivided solid carriers or both, and then, if necessary, shaping theproduct into the desired presentation. For example, a tablet can beprepared by compression or molding, optionally with one or moreaccessory ingredients. Compressed tablets can be prepared by compressingin a suitable machine the active ingredient in a free-flowing form suchas powder or granules, optionally mixed with an excipient such as, butnot limited to, a binder, a lubricant, an inert diluent, and/or asurface active or dispersing agent. Molded tablets can be made bymolding in a suitable machine a mixture of the powdered compoundmoistened with an inert liquid diluent.

This invention further encompasses anhydrous pharmaceutical compositionsand dosage forms comprising an active ingredient, since water canfacilitate the degradation of some compounds. For example, water may beadded (e.g., 5%) in the pharmaceutical arts as a means of simulatinglong-term storage in order to determine characteristics such asshelf-life or the stability of formulations over time. Anhydrouspharmaceutical compositions and dosage forms of the invention can beprepared using anhydrous or low moisture containing ingredients and lowmoisture or low humidity conditions. Pharmaceutical compositions anddosage forms of the invention which contain lactose can be madeanhydrous if substantial contact with moisture and/or humidity duringmanufacturing, packaging, and/or storage is expected. An anhydrouspharmaceutical composition may be prepared and stored such that itsanhydrous nature is maintained. Accordingly, anhydrous compositions maybe packaged using materials known to prevent exposure to water such thatthey can be included in suitable formulary kits. Examples of suitablepackaging include, but are not limited to, hermetically sealed foils,plastic or the like, unit dose containers, blister packs, and strippacks.

An active ingredient can be combined in an intimate admixture with apharmaceutical carrier according to conventional pharmaceuticalcompounding techniques. The carrier can take a wide variety of formsdepending on the form of preparation desired for administration. Inpreparing the compositions for an oral dosage form, any of the usualpharmaceutical media can be employed as carriers, such as, for example,water, glycols, oils, alcohols, flavoring agents, preservatives,coloring agents, and the like in the case of oral liquid preparations(such as suspensions, solutions, and elixirs) or aerosols; or carrierssuch as starches, sugars, micro-crystalline cellulose, diluents,granulating agents, lubricants, binders, and disintegrating agents canbe used in the case of oral solid preparations, in some embodimentswithout employing the use of lactose. For example, suitable carriersinclude powders, capsules, and tablets, with the solid oralpreparations. If desired, tablets can be coated by standard aqueous ornonaqueous techniques.

Binders suitable for use in pharmaceutical compositions and dosage formsinclude, but are not limited to, corn starch, potato starch, or otherstarches, gelatin, natural and synthetic gums such as acacia, sodiumalginate, alginic acid, other alginates, powdered tragacanth, guar gum,cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate,carboxymethyl cellulose calcium, sodium carboxymethyl cellulose),polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch,hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixturesthereof.

Examples of suitable fillers for use in the pharmaceutical compositionsand dosage forms disclosed herein include, but are not limited to, talc,calcium carbonate (e.g., granules or powder), microcrystallinecellulose, powdered cellulose, dextrates, kaolin, mannitol, silicicacid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

Disintegrants may be used in the compositions of the invention toprovide tablets that disintegrate when exposed to an aqueousenvironment. Too much of a disintegrant may produce tablets which maydisintegrate in the bottle. Too little may be insufficient fordisintegration to occur and may thus alter the rate and extent ofrelease of the active ingredient(s) from the dosage form. Thus, asufficient amount of disintegrant that is neither too little nor toomuch to detrimentally alter the release of the active ingredient(s) maybe used to form the dosage forms of the compounds disclosed herein. Theamount of disintegrant used may vary based upon the type of formulationand mode of administration, and may be readily discernible to those ofordinary skill in the art. About 0.5 to about 15 weight percent ofdisintegrant, or about 1 to about 5 weight percent of disintegrant, maybe used in the pharmaceutical composition. Disintegrants that can beused to form pharmaceutical compositions and dosage forms of theinvention include, but are not limited to, agar-agar, alginic acid,calcium carbonate, microcrystalline cellulose, croscarmellose sodium,crospovidone, polacrilin potassium, sodium starch glycolate, potato ortapioca starch, other starches, pre-gelatinized starch, other starches,clays, other algins, other celluloses, gums or mixtures thereof.

Lubricants which can be used to form pharmaceutical compositions anddosage forms of the invention include, but are not limited to, calciumstearate, magnesium stearate, mineral oil, light mineral oil, glycerin,sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid,sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanutoil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, andsoybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, ormixtures thereof. Additional lubricants include, for example, a syloidsilica gel, a coagulated aerosol of synthetic silica, or mixturesthereof. A lubricant can optionally be added, in an amount of less thanabout 1 weight percent of the pharmaceutical composition.

When aqueous suspensions and/or elixirs are desired for oraladministration, the essential active ingredient therein may be combinedwith various sweetening or flavoring agents, coloring matter or dyesand, if so desired, emulsifying and/or suspending agents, together withsuch diluents as water, ethanol, propylene glycol, glycerin and variouscombinations thereof.

The tablets can be uncoated or coated by known techniques to delaydisintegration and absorption in the gastrointestinal tract and therebyprovide a sustained action over a longer period. For example, a timedelay material such as glyceryl monostearate or glyceryl distearate canbe employed. Formulations for oral use can also be presented as hardgelatin capsules wherein the active ingredient is mixed with an inertsolid diluent, for example, calcium carbonate, calcium phosphate orkaolin, or as soft gelatin capsules wherein the active ingredient ismixed with water or an oil medium, for example, peanut oil, liquidparaffin or olive oil. The tablets can be disintegrating tablets forfast release of the therapeutic agent.

Surfactant which can be used to form pharmaceutical compositions anddosage forms of the invention include, but are not limited to,hydrophilic surfactants, lipophilic surfactants, and mixtures thereof.That is, a mixture of hydrophilic surfactants may be employed, a mixtureof lipophilic surfactants may be employed, or a mixture of at least onehydrophilic surfactant and at least one lipophilic surfactant may beemployed.

A suitable hydrophilic surfactant may generally have an HLB value of atleast 10, while suitable lipophilic surfactants may generally have anHLB value of or less than about 10. An empirical parameter used tocharacterize the relative hydrophilicity and hydrophobicity of non-ionicamphiphilic compounds is the hydrophilic-lipophilic balance (“HLB”value). Surfactants with lower HLB values are more lipophilic orhydrophobic, and have greater solubility in oils, while surfactants withhigher HLB values are more hydrophilic, and have greater solubility inaqueous solutions. Hydrophilic surfactants are generally considered tobe those compounds having an HLB value greater than about 10, as well asanionic, cationic, or zwitterionic compounds for which the HLB scale isnot generally applicable. Similarly, lipophilic (i.e., hydrophobic)surfactants are compounds having an HLB value equal to or less thanabout 10.

However, HLB value of a surfactant is merely a rough guide generallyused to enable formulation of industrial, pharmaceutical and cosmeticemulsions.

Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionicsurfactants include, but are not limited to, alkylammonium salts;fusidic acid salts; fatty acid derivatives of amino acids,oligopeptides, and polypeptides; glyceride derivatives of amino acids,oligopeptides, and polypeptides; lecithins and hydrogenated lecithins;lysolecithins and hydrogenated lysolecithins; phospholipids andderivatives thereof; lysophospholipids and derivatives thereof;carnitine fatty acid ester salts; salts of alkylsulfates; fatty acidsalts; sodium docusate; acyl lactylates; mono- and di-acetylatedtartaric acid esters of mono- and di-glycerides; succinylated mono- anddi-glycerides; citric acid esters of mono- and di-glycerides; andmixtures thereof.

Within the aforementioned group, preferred ionic surfactants include, byway of example: lecithins, lysolecithin, phospholipids,lysophospholipids and derivatives thereof; carnitine fatty acid estersalts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyllactylates; mono- and di-acetylated tartaric acid esters of mono- anddi-glycerides; succinylated mono- and di-glycerides; citric acid estersof mono- and di-glycerides; and mixtures thereof.

Ionic surfactants may be the ionized forms of lecithin, lysolecithin,phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol,phosphatidic acid, phosphatidylserine, lysophosphatidylcholine,lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidicacid, lysophosphatidylserine, PEG-phosphatidylethanolamine,PVP-phosphatidylethanolamine, lactylic esters of fatty acids,stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides,mono/diacetylated tartaric acid esters of mono/diglycerides, citric acidesters of mono/diglycerides, cholylsarcosine, caproate, caprylate,caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate,linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate,lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, andsalts and mixtures thereof.

Hydrophilic non-ionic surfactants may include, but not limited to,alkylglucosides; alkylmaltosides; alkylthioglucosides; laurylmacrogolglycerides; polyoxyalkylene alkyl ethers such as polyethyleneglycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethyleneglycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esterssuch as polyethylene glycol fatty acids monoesters and polyethyleneglycol fatty acids diesters; polyethylene glycol glycerol fatty acidesters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fattyacid esters such as polyethylene glycol sorbitan fatty acid esters;hydrophilic transesterification products of a polyol with at least onemember of the group consisting of glycerides, vegetable oils,hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylenesterols, derivatives, and analogues thereof; polyoxyethylated vitaminsand derivatives thereof; polyoxyethylene-polyoxypropylene blockcopolymers; and mixtures thereof; polyethylene glycol sorbitan fattyacid esters and hydrophilic transesterification products of a polyolwith at least one member of the group consisting of triglycerides,vegetable oils, and hydrogenated vegetable oils. The polyol may beglycerol, ethylene glycol, polyethylene glycol, sorbitol, propyleneglycol, pentaerythritol, or a saccharide.

Other hydrophilic-non-ionic surfactants include, without limitation,PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate,PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate,PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryllaurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenatedcastor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides,polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitanlaurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearylether, tocopheryl PEG-100 succinate, PEG-24 cholesterol,polyglyceryl-10oleate, Tween 40, Tween 60, sucrose monostearate, sucrosemonolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG15-100 octyl phenol series, and poloxamers.

Suitable lipophilic surfactants include, by way of example only: fattyalcohols; glycerol fatty acid esters; acetylated glycerol fatty acidesters; lower alcohol fatty acids esters; propylene glycol fatty acidesters; sorbitan fatty acid esters; polyethylene glycol sorbitan fattyacid esters; sterols and sterol derivatives; polyoxyethylated sterolsand sterol derivatives; polyethylene glycol alkyl ethers; sugar esters;sugar ethers; lactic acid derivatives of mono- and di-glycerides;hydrophobic transesterification products of a polyol with at least onemember of the group consisting of glycerides, vegetable oils,hydrogenated vegetable oils, fatty acids and sterols; oil-solublevitamins/vitamin derivatives; and mixtures thereof. Within this group,preferred lipophilic surfactants include glycerol fatty acid esters,propylene glycol fatty acid esters, and mixtures thereof, or arehydrophobic transesterification products of a polyol with at least onemember of the group consisting of vegetable oils, hydrogenated vegetableoils, and triglycerides.

In one embodiment, the composition may include a solubilizer to ensuregood solubilization and/or dissolution of the dopaminergic agent and/ornicotinic receptor modulator and to minimize precipitation of thedopaminergic agent and/or nicotinic receptor modulator. This can beespecially important for compositions for non-oral use, e.g.,compositions for injection. A solubilizer may also be added to increasethe solubility of the hydrophilic drug and/or other components, such assurfactants, or to maintain the composition as a stable or homogeneoussolution or dispersion.

Examples of suitable solubilizers include, but are not limited to, thefollowing: alcohols and polyols, such as ethanol, isopropanol, butanol,benzyl alcohol, ethylene glycol, propylene glycol, butanediols andisomers thereof, glycerol, pentaerythritol, sorbitol, mannitol,transcutol, dimethyl isosorbide, polyethylene glycol, polypropyleneglycol, polyvinylalcohol, hydroxypropyl methylcellulose and othercellulose derivatives, cyclodextrins and cyclodextrin derivatives;ethers of polyethylene glycols having an average molecular weight ofabout 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether(glycofurol) or methoxy PEG; amides and other nitrogen-containingcompounds such as 2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam,N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone,N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esterssuch as ethyl propionate, tributylcitrate, acetyl triethylcitrate,acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate,ethyl butyrate, triacetin, propylene glycol monoacetate, propyleneglycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactoneand isomers thereof, β-butyrolactone and isomers thereof; and othersolubilizers known in the art, such as dimethyl acetamide, dimethylisosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycolmonoethyl ether, and water.

Mixtures of solubilizers may also be used. Examples include, but notlimited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate,dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone,polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropylcyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol,transcutol, propylene glycol, and dimethyl isosorbide. Particularlypreferred solubilizers include sorbitol, glycerol, triacetin, ethylalcohol, PEG-400, glycofurol and propylene glycol.

The amount of solubilizer that can be included is not particularlylimited. The amount of a given solubilizer may be limited to abioacceptable amount, which may be readily determined by one of skill inthe art. In some circumstances, it may be advantageous to includeamounts of solubilizers far in excess of bioacceptable amounts, forexample to maximize the concentration of the drug, with excesssolubilizer removed prior to providing the composition to a patientusing conventional techniques, such as distillation or evaporation.Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%,50%, 100%, or up to about 200% by weight, based on the combined weightof the drug, and other excipients. If desired, very small amounts ofsolubilizer may also be used, such as 5%, 2%, 1% or even less.Typically, the solubilizer may be present in an amount of about 1% toabout 100%, more typically about 5% to about 25% by weight.

The composition can further include one or more pharmaceuticallyacceptable additives and excipients. Such additives and excipientsinclude, without limitation, detackifiers, anti-foaming agents,buffering agents, polymers, antioxidants, preservatives, chelatingagents, viscomodulators, tonicifiers, flavorants, colorants, odorants,opacifiers, suspending agents, binders, fillers, plasticizers,lubricants, and mixtures thereof.

In addition, an acid or a base may be incorporated into the compositionto facilitate processing, to enhance stability, or for other reasons.Examples of pharmaceutically acceptable bases include amino acids, aminoacid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide,sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate,magnesium hydroxide, magnesium aluminum silicate, synthetic aluminumsilicate, synthetic hydrocalcite, magnesium aluminum hydroxide,disopropylethylamine, ethanolamine, ethylenediamine, triethanolamine,triethylamine, trisopropanolamine, trimethylamine,tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable arebases that are salts of a pharmaceutically acceptable acid, such asacetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonicacid, amino acids, ascorbic acid, benzoic acid, boric acid, butyricacid, carbonic acid, citric acid, fatty acids, formic acid, fumaricacid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lacticacid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionicacid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinicacid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonicacid, uric acid, and the like. Salts of polyprotic acids, such as sodiumphosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphatecan also be used. When the base is a salt, the cation can be anyconvenient and pharmaceutically acceptable cation, such as ammonium,alkali metals, alkaline earth metals, and the like. Example may include,but not limited to, sodium, potassium, lithium, magnesium, calcium andammonium.

Suitable acids are pharmaceutically acceptable organic or inorganicacids. Examples of suitable inorganic acids include hydrochloric acid,hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boricacid, phosphoric acid, and the like. Examples of suitable organic acidsinclude acetic acid, acrylic acid, adipic acid, alginic acid,alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boricacid, butyric acid, carbonic acid, citric acid, fatty acids, formicacid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbicacid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid,para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid,salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid,thioglycolic acid, toluenesulfonic acid, uric acid and the like.

Pharmaceutical compositions for injection In some embodiments, theinvention provides a pharmaceutical composition for injection containingan agent that reduces or eliminate a side effect of a dopaminergicagent. In some embodiments, the invention provides a pharmaceuticalcomposition for injection containing a combination of a dopaminergicagent and an agent that reduces or eliminates a side effect of thedopaminergic agent, and a pharmaceutical excipient suitable forinjection. Components and amounts of agents in the compositions are asdescribed herein.

The forms in which the novel compositions of the present invention maybe incorporated for administration by injection include aqueous or oilsuspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, orpeanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueoussolution, and similar pharmaceutical vehicles.

Aqueous solutions in saline are also conventionally used for injection.Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and thelike (and suitable mixtures thereof), cyclodextrin derivatives, andvegetable oils may also be employed. The proper fluidity can bemaintained, for example, by the use of a coating, such as lecithin, bythe maintenance of the required particle size in the case of dispersionand by the use of surfactants. The prevention of the action ofmicroorganisms can be brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like.

Sterile injectable solutions are prepared by incorporating the nicotinicreceptor modulator and/or the dopaminergic agent in the required amountin the appropriate solvent with various other ingredients as enumeratedabove, as required, followed by filtered sterilization. Generally,dispersions are prepared by incorporating the various sterilized activeingredients into a sterile vehicle which contains the basic dispersionmedium and the required other ingredients from those enumerated above.In the case of sterile powders for the preparation of sterile injectablesolutions, the preferred methods of preparation are vacuum-drying andfreeze-drying techniques which yield a powder of the active ingredientplus any additional desired ingredient from a previouslysterile-filtered solution thereof.

Pharmaceutical compositions for topical (e.g., transdermal) delivery Insome embodiments, the invention provides a pharmaceutical compositionfor transdermal delivery containing a nicotinic receptor modulator thatreduces or eliminates a side effect of a dopaminergic agent, and apharmaceutical excipient suitable for transdermal delivery. In someembodiments, the invention provides a pharmaceutical composition fortransdermal delivery containing a combination of a dopaminergic agentand a nicotinic receptor modulator that reduces or eliminates a sideeffect of the dopaminergic agent, and a pharmaceutical excipientsuitable for transdermal delivery. In some embodiments, the nicotinicreceptor modulator that reduces or eliminates the side effect of thedopaminergic agent is a nicotinic receptor agonist, e.g. nicotine, asdescribed elsewhere herein. Components and amounts of nicotinic receptormodulators in the compositions are as described herein.

Compositions of the present invention can be formulated intopreparations in solid, semi-solid, or liquid forms suitable for local ortopical administration, such as gels, water soluble jellies, creams,lotions, suspensions, foams, powders, slurries, ointments, solutions,oils, pastes, suppositories, sprays, emulsions, saline solutions,dimethylsulfoxide (DMSO)-based solutions. In general, carriers withhigher densities are capable of providing an area with a prolongedexposure to the active ingredients. In contrast, a solution formulationmay provide more immediate exposure of the active ingredient to thechosen area.

The pharmaceutical compositions also may comprise suitable solid or gelphase carriers or excipients, which are compounds that allow increasedpenetration of, or assist in the delivery of, therapeutic moleculesacross the stratum corneum permeability barrier of the skin. There aremany of these penetration-enhancing molecules known to those trained inthe art of topical formulation. Examples of such carriers and excipientsinclude, but are not limited to, humectants (e.g., urea), glycols (e.g.,propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleicacid), surfactants (e.g., isopropyl myristate and sodium laurylsulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes(e.g., menthol), amines, amides, alkanes, alkanols, water, calciumcarbonate, calcium phosphate, various sugars, starches, cellulosederivatives, gelatin, and polymers such as polyethylene glycols.

Another formulation for use in the methods of the present inventionemploys transdermal delivery devices (e.g. patches or minipumps). Suchtransdermal devices may be used to provide continuous or discontinuousinfusion of the nicotinic receptor modulator in controlled amounts,either with or without dopaminergic agent. Thus, in some embodiments theinvention provides a transdermal device incorporating a nicotinicreceptor modulator, e.g., an agonist such as nicotine. In someembodiments the invention provides a transdermal device incorporating anicotinic receptor modulator, e.g., an agonist such as nicotine incombination with a dopaminergic agent, e.g. levodopa.

The construction and use of transdermal devices for the delivery ofpharmaceutical agents is well known in the art. See, e.g., U.S. Pat.Nos. 5,023,252, 4,992,445 and 5,001,139. Such devices may be constructedfor continuous, pulsatile, or on demand delivery of pharmaceuticalagents.

Pharmaceutical compositions for inhalation. Compositions for inhalationor insufflation include solutions and suspensions in pharmaceuticallyacceptable, aqueous or organic solvents, or mixtures thereof, andpowders. The liquid or solid compositions may contain suitablepharmaceutically acceptable excipients as described supra. Preferablythe compositions are administered by the oral or nasal respiratory routefor local or systemic effect. Compositions in preferablypharmaceutically acceptable solvents may be nebulized by use of inertgases. Nebulized solutions may be inhaled directly from the nebulizingdevice or the nebulizing device may be attached to a face mask tent, orintermittent positive pressure breathing machine. Solution, suspension,or powder compositions may be administered, preferably orally ornasally, from devices that deliver the formulation in an appropriatemanner.

Other pharmaceutical compositions Pharmaceutical compositions may alsobe prepared from compositions described herein and one or morepharmaceutically acceptable excipients suitable for sublingual, buccal,rectal, intraosseous, intraocular, intranasal, epidural, or intraspinaladministration. Preparations for such pharmaceutical compositions arewell-known in the art. See, e.g., See, e.g., Anderson, Philip O.;Knoben, James E.; Troutman, William G, eds., Handbook of Clinical DrugData, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds.,Principles of Drug Action, Third Edition, Churchill Livingston, NewYork, 1990; Katzung, ed., Basic and Clinical Pharmacology, NinthEdition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., ThePharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001;Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams &Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-SecondEdition (The Pharmaceutical Press, London, 1999); all of which areincorporated by reference herein in their entirety.

B. Kits

The invention also provides kits. The kits include a nicotinic receptormodulator that reduces or eliminates a side effect of a dopaminergicagent, in suitable packaging, and written material that can includeinstructions for use, discussion of clinical studies, listing of sideeffects, and the like. The kit may further contain a dopaminergic agentthat has a side effect. In some embodiments, the dopaminergic agent andthe nicotinic receptor modulator that reduces or eliminates a sideeffect of the dopaminergic agent are provided as separate compositionsin separate containers within the kit. In some embodiments, thedopaminergic agent and the nicotinic receptor modulator that reduces oreliminates a side effect of the dopaminergic agent are provided as asingle composition within a container in the kit. Suitable packaging andadditional articles for use (e.g., measuring cup for liquidpreparations, foil wrapping to minimize exposure to air, and the like)are known in the art and may be included in the kit.

Methods

In another aspect, the invention provides methods, including methods oftreatment and methods of enhancing a therapeutic effect of a substance.

The term “animal” or “animal subject” as used herein includes humans aswell as other mammals. The methods generally involve the administrationof one or more drugs for the treatment of one or more diseases.Combinations of agents can be used to treat one disease or multiplediseases or to modulate the side-effects of one or more agents in thecombination.

The term “treating” and its grammatical equivalents as used hereinincludes achieving a therapeutic benefit and/or a prophylactic benefit.By therapeutic benefit is meant eradication or amelioration of theunderlying disorder being treated. Also, a therapeutic benefit isachieved with the eradication or amelioration of one or more of thephysiological symptoms associated with the underlying disorder such thatan improvement is observed in the patient, notwithstanding that thepatient may still be afflicted with the underlying disorder. Forprophylactic benefit, the compositions may be administered to a patientat risk of developing a particular disease, or to a patient reportingone or more of the physiological symptoms of a disease, even though adiagnosis of this disease may not have been made.

In some embodiments, the invention provides a method of treating acondition by administering to an animal suffering from the condition aneffective amount of a nicotinic receptor modulator sufficient to reduceor eliminate a side effect associated with a dopaminergic agent. In someembodiments, the nicotinic receptor modulator reduces or eliminates aplurality of side effects associated with the dopaminergic agent. Insome embodiments the animal is a mammal, e.g., a human.

In some embodiments, the invention provides a method of treating acondition by administering to an animal suffering from the condition aneffective amount of a dopaminergic agent and an amount of a nicotinicreceptor modulator sufficient to reduce or eliminate a side effect ofthe dopaminergic agent. In some embodiments, the modulator reduces oreliminates a plurality of side effects of the dopaminergic agent. Insome embodiments the animal is a mammal, e.g., a human.

The dopaminergic agent and the nicotinic receptor modulator areco-administered. “Co-administration,” “administered in combinationwith,” and their grammatical equivalents, as used herein, encompassesadministration of two or more agents to an animal so that both agentsand/or their metabolites are present in the animal at the same time.Co-administration includes simultaneous administration in separatecompositions, administration at different times in separatecompositions, or administration in a composition in which both agentsare present. Thus, in some embodiments, the nicotinic receptor modulatorand the dopaminergic agent are administered in a single composition. Insome embodiments, the dopaminergic agent and the nicotinic receptormodulator are admixed in the composition. Typically, the dopaminergicagent is present in the composition in an amount sufficient to produce atherapeutic effect, and the nicotinic receptor modulator is present inthe composition in an amount sufficient to reduce a side effect of thedopaminergic agent. In some embodiments, the dopaminergic agent ispresent in an amount sufficient to exert a therapeutic effect and thenicotinic receptor modulator is present in an amount sufficient todecrease a side effect of the dopaminergic agent by an average of atleast about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than90%, or substantially eliminate a side effect, compared to the effectwithout nicotinic receptor modulator. In some embodiments thedopaminergic agent and the nicotinic receptor modulator areco-administered to an individual every time than a therapeutic effectfrom said dopaminergic agent is desired in said individual. In someembodiment, co-administration comprises simultaneous administration ofsaid dopaminergic agent and nicotine in the same dosage form orsimultaneous administration in separate dosage forms. In someembodiments, the dopaminergic agent is present at an amount that is 100percent to about 75% of the effective amount when the dopaminergic agentis administered alone.

In some embodiments, the dopaminergic agent is present in an amountsufficient to exert a therapeutic effect and the nicotinic receptormodulator is present in an amount sufficient to reduce or eliminate aside effect of the dopaminergic agent within at least about 1, 5, 10,15, 20, 25, 30, 40, 50, 60, 70, 80, or 90 minutes after administrationof the dopaminergic agent.

In some embodiments, the dopaminergic agent and/or the nicotinicreceptor modulator are co-administered with an effective amount of anagent such as carbidopa, which blocks the conversion of levodopa todopamine in the blood. In some embodiments, the dopaminergic agentand/or the nicotinic receptor modulator are co-administered with aneffective amount of a COMT Inhibitor, such as entacapone. In someembodiments, the dopaminergic agent and/or the nicotinic receptormodulator are co-administered with an effective amount of a monoamineoxidase type B (MAO-B) inhibitor such as selegiline. In someembodiments, the dopaminergic agent and the nicotinic receptor modulatorare co-administered with an effective amount of amantadine.

Administration of the dopaminergic agent and the nicotinic receptormodulator that reduces or eliminates at least one side effect of thedopaminergic agent may be any suitable means. If the agents areadministered as separate compositions, they may be administered by thesame route or by different routes. If the agents are administered in asingle composition, they may be administered by any suitable route. Insome embodiments, the agents are administered as a single composition byoral administration. In some embodiments, the agents are administered asa single composition by transdermal administration. In some embodiments,the agents are administered as a single composition by injection. Insome embodiments the dopaminergic agent and the nicotinic receptormodulator are administered as a single composition to an individualevery time than a therapeutic effect from said dopaminergic agent isdesired in said individual. In some embodiments, the dopaminergic agentis present at an amount that is 100 percent to about 75% of theeffective amount when the dopaminergic agent is administered alone. Insome embodiments, the dopaminergic agent is administered in an amountsufficient to exert a therapeutic effect and the nicotinic receptormodulator is administered in an amount sufficient to reduce or eliminatea side effect of the dopaminergic agent within at least about 1, 5, 10,15, 20, 25, 30, 40, 50, 60, 70, 80, or 90 minutes after administrationof the dopaminergic agent.

In some embodiments, the nicotinic receptor modulator that reduces oreliminates a side effect of a dopaminergic agent is a nicotinic receptoragonist, nicotinic receptor agonists are as described herein. In someembodiments, nicotine is used. Dosages are as provided for compositions.Typically, the daily dosage of the nicotinic receptor modulator will beabout 0.05 to about 100 mg/kg. In some embodiments, the daily dosage ofthe nicotinic receptor modulator is less than 93 mg per day.

The dopaminergic agent may be any dopaminergic agent described herein.In some embodiments, the dopaminergic agent is levodopa or a dopamineagonist, as described herein.

The methods of the invention may be used for treatments of any suitablecondition where one or more dopaminergic agents are used that have sideeffects. Examples of conditions include, but are not limited to,Parkinson's disease, Alzheimer, dopa-responsive dystonia, cerebralpalsy, postischemic contractile dysfunction, severe ovarianhyperstimulation syndrome, pediatric movement disorders and non-oliguricrenal failure.

For example, in some embodiments, the methods of the invention includethe treatment of Parkinson's disease patient to prevent dyskinesias byadministering to an animal in need of treatment an effective amount of adopaminergic agent, such as levodopa, and an effective amount of anagent that reduces or eliminates a dyskinesias induced by thedopaminergic agent.

In other embodiments, the methods of the invention include the treatmentof postischemic contractile dysfunction by administering to an animal inneed of treatment an effective amount of a dopaminergic agent, such aslevodopa, and an effective amount of nicotinic receptor modulator thatreduces or eliminates a side effect of the dopaminergic agent.

In yet other embodiments, the methods of the invention include thetreatment of severe ovarian hyperstimulation syndrome by administeringto an animal in need of treatment an effective amount of a dopaminergicagent, such as levodopa, and an effective amount of an agent thatreduces or eliminates a side effect of the dopaminergic agent.

In other embodiments, the methods of the invention include the treatmentof pediatric movement disorders by administering to an animal in need oftreatment an effective amount of a dopaminergic agent, such as levodopa,and an effective amount of an agent that reduces or eliminates a sideeffect of the dopaminergic agent.

In some embodiments, the methods of the invention include the treatmentof non-oliguric renal failure by administering to an animal in need oftreatment an effective amount of a dopaminergic agent, such as levodopa,and an effective amount of an agent that reduces or eliminates a sideeffect of the dopaminergic agent.

When a dopaminergic agent and a nicotinic receptor modulator thatreduces or eliminates a side effect of the dopaminergic agent are usedin combination, any suitable ratio of the two agents, e.g., molar ratio,w/w ratio, w/v ratio, or v/v ratio, as described herein, may be used. Insome embodiments, the dopaminergic agent is present at an amount that is100 percent to about 75% of the effective amount when the dopaminergicagent is administered alone.

The invention further provides methods of reversing one or more sideeffects of a dopaminergic agent by administering nicotinic receptormodulator to an animal that has received an amount of the dopaminergicagent sufficient to produce one or more side effects. The methods areespecially useful in a situation where it is desired to rapidly reverseone or more side effects of a dopaminergic agent. Any suitable nicotinicreceptor modulator described herein may be used.

In some embodiments, the invention provides a method for reversing aside effect of a dopaminergic agent in a human by administering to thehuman an amount of a nicotinic receptor modulator sufficient topartially or completely reverse a side effect of the dopaminergic agent,where the human has received an amount of said dopaminergic agentsufficient to produce a side effect. In some embodiments, the human hasreceived an overdose of the dopaminergic agent producing the sideeffect. In some embodiments, the nicotinic receptor modulator is anagonist, such as nicotine. Typically, the agonist will be administeredby oral administration or transdermal delivery, in a dose sufficient topartially or completely reverse a side effect of the dopaminergic agent.In some embodiments, the agonist will be delivered by pulsatiledelivery. In some embodiments, the agonist is administered in an amountsufficient to reduce or eliminate a side effect of the dopaminergicagent within at least about 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70,80, or 90 minutes after administration of the dopaminergic agent.

In another aspect, the invention includes method for the reducingdyskinesias comprising administering an animal suffering fromdyskinesias an amount of a nicotinic receptor modulator sufficient toreduce the dyskinesias.

In some embodiments, the nicotinic receptor modulator is an agonist oran antagonist as described herein. In some embodiments, the nicotinicreceptor agonist modulates a nicotinic receptor comprising at least one

subunit or a nicotinic receptor containing at least one

subunit and at least one β subunit. In some embodiments, the α subunitis selected from the group consisting of α2, α3, α4, α5, α6, α7, α8, α9,and α10 and the β subunit is selected from the group consisting of β2,β3 and β4. In some embodiments, the nicotinic receptor agonist modulatesa nicotinic receptor composed of subunits selected from the groupconsisting of α4β2, α6β2, α4α6β2, α4α5β2 α4α6β2β3, α6β2β3 and α4α2β2. Insome embodiments, the nicotinic receptor modulator modulates a nicotinicreceptor comprising at least one α subunit selected from the groupconsisting of α4, α6, and α7.

Administration

The methods involve the administration of a nicotinic receptormodulator, e.g., to reduce or eliminate a side effect of a dopaminergicagent. In some embodiments, a dopaminergic agent that produces a sideeffect is administered in combination with a nicotinic receptormodulator that reduces the effects of a side effect of the dopaminergicagent. In some embodiments, other agents are also administered, e.g.,other dopaminergic agents or other therapeutic agent. When two or moreagents are co-administered, they may be co-administered in any suitablemanner, e.g., as separate compositions, in the same composition, by thesame or by different routes of administration. In some embodiments, thenicotine receptor modulator and/or the dopaminergic agent areadministered to the upper gastrointestinal tract of a subject.

In some embodiments, the nicotinic receptor modulator that reduces oreliminates a side effect of a dopaminergic agent is administered in asingle dose. This may be the case where the agent is introduced into ananimal to quickly lower the side effect of a dopaminergic agent alreadypresent in the body. Typically, such administration will be byinjection, e.g., intravenous injection, in order to introduce thenicotinic receptor modulator quickly. However, other routes may be usedas appropriate. A single dose of an agent that reduces or eliminates aside effect of a dopaminergic agent may also be used when it isadministered with the dopaminergic agent (e.g., a dopaminergic agentthat produces a side effect) for treatment of an acute condition.

In some embodiments, the nicotinic receptor modulator that reduces oreliminates a side effect of a dopaminergic agent is administered inmultiple doses. Dosing may be about once, twice, three times, fourtimes, five times, six times, or more than six times per day. Dosing maybe about once a month, once every two weeks, once a week, or once everyother day. In one embodiment the dopaminergic agent is levodopa. Inanother embodiment the dopaminergic agent and the nicotinic receptormodulator are administered together about once per day to about 6 timesper day. In some embodiments, the nicotinic receptor modulator and thedopaminergic agent are administered to an individual every time than atherapeutic effect from said dopaminergic agent is desired in saidindividual. In another embodiment the administration of the dopaminergicagent and the nicotinic receptor modulator continues for less than about7 days. In yet another embodiment the administration continues for morethan about 6, 10, 14, 28 days, two months, six months, or one year. Insome cases, continuous dosing is achieved and maintained as long asnecessary. In some embodiments, the nicotinic receptor modulator thatreduces or eliminates a side effect of a substance and/or dopaminergicagent is administered continually or in a pulsatile manner, e.g. with aminipump, patch or stent.

Administration of the nicotinic receptor modulator of the invention maycontinue as long as necessary. In some embodiments, an agent of theinvention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, 28 daysor 1 year. In some embodiments, an agent of the invention isadministered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In someembodiments, an agent of the invention is administered chronically on anongoing basis, e.g., for the treatment of chronic effects.

In some embodiments, a composition comprising a nicotinic receptormodulator is administered to an individual to reduce or eliminate a sideeffect of a dopaminergic agent in said individual, wherein the releaseof the nicotinic receptor modulator from a composition reduces oreliminates the side effect the dopaminergic agent. In some embodiments,in order to eliminate or reduce the side effects of a dopaminergic agentthe nicotinic receptor modulator or a metabolite of the nicotinicreceptor modulator can be present in the bloodstream prior to thedopaminergic agent. For example, this may be accomplished byadministering the nicotinic receptor modulator separately from thedopaminergic agent or by administering the nicotinic receptor modulatorand the dopaminergic agent in the same composition that is formulated sothat the nicotinic receptor modulator reaches the bloodstream before thedopaminergic agent. For example, as desired a dosage form can be usedwherein one active agent is immediate release and the other agent isslow/delayed release (e.g., bilayered tablet comprising both agents).Examples of multidrug dosage forms for differential release are known,such as disclosed in U.S. Pat. Nos. 7,011,849; 6,221,394; 5,073,380;20070104787; 20060204578; 20060057202; 20050276852 and 20050266032.

In some embodiments, the nicotinic receptor modulator and/or thedopaminergic agent are formulated into orally disintegrating tabletsthat dissolve rapidly. These tablets can be swallowed with or withoutwater. Examples of orally disintegrating tablets are known, such asdisclosed in U.S. Pat. Nos. 7,282,217; 7,229,641; 6,368,625; 6,365,182;6,221,392; and 6,024,981.

In some embodiments, the nicotinic receptor modulator or a metabolite ofthe nicotinic receptor modulator is in the blood 48, 36, 24, 12, 10, 8,6, 5, 4, 3, 2, 1 hours before the dopaminergic agent. In otherembodiments, the nicotinic receptor modulator or a metabolite of thenicotinic receptor modulator is in the blood stream 59, 50, 40, 35, 30,25 20, 10, 5, 4, 3, 2, 1 minutes before the dopaminergic agent.

In another aspect of the invention, in order to eliminate or reduces theside effects of a dopaminergic agent the nicotinic receptor modulator ora metabolite of the nicotinic receptor modulator may be in thebloodstream after the dopaminergic agent. This may be accomplished byadministering the nicotinic receptor modulator separately from thedopaminergic agent or by administering the nicotinic receptor modulatorand the dopaminergic agent in the same composition that is formulated sothat the nicotinic receptor modulator reaches the bloodstream after thedopaminergic agent.

In some embodiments, the nicotinic receptor modulator or a metabolite ofthe nicotinic receptor modulator is present in the blood 48, 36, 24, 12,10, 8, 6, 5, 4, 3, 2, 1 hours after the dopaminergic agent. In someembodiments, the nicotinic receptor modulator or a metabolite of thenicotinic receptor modulator is in the blood stream 59, 50, 40, 35, 30,25 20, 10, 5, 4, 3, 2, 1 minutes after the dopaminergic agent.

In one embodiment, nicotinic receptor modulator or a metabolite has asecond plasma half-life that differs from the first plasma half-life byat least about 3 hours, wherein a dosage form administered provides aplasma concentration within a therapeutic range of the dopaminergicagent over a period which is coextensive with at least about 70% of aperiod over which the dosage form provides a plasma concentration withina therapeutic range of nicotinic receptor modulator or a metabolite. Insome embodiments the nicotinic receptor modulator or a metabolite andthe dopaminergic agent have a similar half-life. In some embodiments,the half life of the nicotinic receptor modulator or a metabolite of thenicotinic receptor modulator is 48, 36, 24, 12, 10, 8, 6, 5, 4, 3, 2,1.5, 1 hours.

In some embodiments, a dosage form of the invention comprises amulti-layered tablet. In one embodiment, a dosage form of the inventioncomprises a bi-layered tablet which comprises a first layer and a secondlayer, the first layer comprising nicotinic receptor modulator or ametabolite and has a first plasma half-life, and the second layercomprising the dopaminergic agent which has a second plasma half-lifethat differs from the first plasma half-life by at least about 3 hours,wherein the bi-layered tablet provides a plasma concentration within atherapeutic range of the dopaminergic agent over a period which iscoextensive with at least about 70% of a period over which thebi-layered tablet provides a plasma concentration within a therapeuticrange of the nicotinic receptor modulator or a metabolite.

In yet other embodiments, the second and first plasma half-life differby at least 48, 36, 24, 12, 10, 8, 6, 5, 4, 3, 2, or 1 hour. In someembodiments the second and first plasma half-life are similar.

In some embodiments, the invention includes a multilayer tabletcomprising an immediate release layer and a sustained release layer. Insome embodiments, the immediate release layer comprises a nicotinicreceptor modulator or a metabolite and the sustained release layercomprises a dopaminergic agent. In some embodiments, the immediaterelease layer comprises one or more therapeutic agents independentlyselected from the group consisting of nicotinic receptor agonist anddopaminergic agent, and the sustained release layer comprises one ormore therapeutic agents independently selected from the group consistingof nicotinic receptor agonist and dopaminergic agents. In someembodiments, the immediate release layer comprises a dopaminergic agentand the sustain release layer comprises a nicotinic receptor modulatoror a metabolite. In some embodiments, the immediate release layer or thesustained release layer comprises a third therapeutic agent such as theones described herein. Examples of agents include, but are not limitedto, amantadine, carbidopa and entacapone.

An effective amount of a nicotinic receptor modulator and/or aneffective amount of a dopaminergic agent may be administered in eithersingle or multiple doses by any of the accepted modes of administrationof agents having similar utilities, including rectal, buccal, intranasaland transdermal routes, by intra-arterial injection, intravenously,intraperitoneally, parenterally, intramuscularly, subcutaneously,orally, topically, as an inhalant, or via an impregnated or coateddevice such as a stent.

In some embodiments, an effective amount of a nicotinic receptormodulator is administered such that the nicotinic receptor modulatorreaches a critical concentration in the bloodstream, plasma, or thetissue where the side effect need to be eliminated, wherein the criticalconcentration is the concentration necessary to reduce or eliminate thedopaminergic agent induced-side effect. Examples of different forms ofadministration include, but are not limited to, administration in asingle dose, multiple doses or through pulsatile administration. In someembodiments, after the nicotinic receptor modulator or a metabolite ofthe nicotinic receptor modulator has reduced or eliminated thedopaminergic agent induced-side effect, the concentration of thenicotine receptor modulator or a metabolite of the nicotine receptormodulator will decrease at the site of side effects occur (e.g.,systemically, such as in the bloodstream; or the tissue where the sideeffect occurs).

In some embodiments, the nicotinic receptor modulator is administeredsuch that the nicotinic receptor modulator or a metabolite of a receptormodulator reaches a critical concentration in the bloodstream, plasma ortissue where the side effect needs to be eliminated 48, 36, 24, 12, 10,8, 6, 5, 4, 3, 2, 1 hours before the dopaminergic agent reaches thebloodstreams or the tissue where the side effects are generated. In someembodiments, the nicotinic receptor modulator is administered such thatthe nicotinic receptor modulator or a metabolite of the nicotinicreceptor modulator reaches a critical concentration in the bloodstream,plasma or tissue where the side effect needs to be eliminated 59, 50,40, 35, 30, 25 20, 10, 5, 4, 3, 2, 1 minutes before the dopaminergicagent reaches the bloodstreams or the tissue where the side effects aregenerated.

In some embodiments, the nicotinic receptor modulator is administeredsuch that the nicotinic receptor modulator or a metabolite of a receptormodulator reaches a critical concentration in the bloodstream, plasma ortissue where the side effect needs to be eliminated 48, 36, 24, 12, 10,8, 6, 5, 4, 3, 2, 1 hours after the dopaminergic agent reaches thebloodstreams or the tissue where the side effects are generated. In someembodiments, the nicotinic receptor modulator is administered such thatthe nicotinic receptor modulator or a metabolite of the nicotinicreceptor modulator reaches a critical concentration in the bloodstream,plasma or tissue where the side effect needs to be eliminated 59, 50,40, 35, 30, 25 20, 10, 5, 4, 3, 2, 1 minutes after the dopaminergicagent reaches the bloodstream, plasma or the tissue where the sideeffects are generated.

In some embodiments, the nicotinic receptor modulator is administeredsuch that a critical concentration of the nicotinic receptor modulatorand or a metabolite of the nicotinic receptor modulator is reached inthe bloodstream, plasma or a tissue where the side effect needs to beeliminated when the side effect reaches a peak. In some embodiments, isadministered such that a critical concentration of the nicotinicreceptor modulator and or a metabolite of the nicotinic receptormodulator is reached in the bloodstream, plasma or a tissue where theside effect needs to be eliminated 48, 36, 24, 12, 10, 8, 6, 5, 4, 3, 2,1 hours before the side effect eliminated reaches a peak. In someembodiments, is administered such that a critical concentration of thenicotinic receptor modulator and or a metabolite of the nicotinicreceptor modulator is reached in the bloodstream, plasma or a tissuewhere the side effect needs to be eliminated 59, 50, 40, 35, 30, 25 20,10, 5, 4, 3, 2, 1 minutes before the side effect eliminated reaches apeak.

In some embodiment, the critical concentration of the nicotinic receptormodulator or a nicotinic receptor modulator metabolite is about 1 pg/mlto about 1 mg/ml. In some embodiments the critical concentrationnicotinic receptor modulator or nicotinic receptor modulator metaboliteis about 1 pg/ml to about 1 ng/ml, or about 50 pg/ml to about 1 ng/ml,or about 100 pg/ml to about 1 ng/ml, or about 500 pg/ml to about 1ng/ml, or about 1 ng/ml to about 500 ng/ml, or about 10 ng/ml to about500 ng/ml, or about 100 ng/ml to about 500 ng/ml, or about 200 ng/ml toabout 500 ng/ml, or about 300 ng/ml to about 500 ng/ml, or about 400ng/ml to about 500 ng/ml, or about 500 ng/ml to about 1 ug/ml, or about600 ng/ml to about 1 ug/ml, or about 700 ng/ml to about 1 ug/ml, orabout 800 ng/ml to about 1 ug/ml, or about 900 ng/ml to about 1 ug/ml,or about 1 ug/ml to about 1 mg/ml, or about 10 ug/ml to about 1 mg/ml,or about 100 ug/ml to about 1 mg/ml, or about 500 ug/ml to about 1mg/ml, or about 600 ug/ml to about 1 mg/ml, or about 700 ug/ml to about1 mg/ml, or about 800 ug/ml to about 1 mg/ml, or about 900 ug/ml toabout 1 mg/ml. In some embodiment, the critical concentration of thenicotinic receptor modulator or a nicotinic receptor modulatormetabolite is about 200 ng/ml to about 420 ng/ml. In some embodiment,the critical concentration of the nicotinic receptor modulator or anicotinic receptor modulator metabolite is about 1 ng/ml to about 20ng/ml. In some embodiment, the critical concentration of the nicotinicreceptor modulator or a nicotinic receptor modulator metabolite is about1 ng/ml to about 5 ng/ml. In some embodiment, the critical concentrationof the nicotinic receptor modulator or a nicotinic receptor modulatormetabolite is about 20 ng/ml to about 100 ng/ml.

In some embodiments, the nicotinic receptor modulator is administeredsuch that the nicotinic receptor modulator or a metabolite reduce oreliminate a side effect of a dopaminergic agent within at least about 1,5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90 minutes afteradministration of the dopaminergic agent.

The nicotinic receptor modulator and the dopaminergic agent may beadministered in dosages as described herein (see, e.g., Compositions).Dosing ranges for dopaminergic agents are known in the art. It is alsoknown in the art that due to intersubject variability in dopaminergicagents, such as levodopa, pharmacokinetics, individualization of dosingregimen is necessary for optimal therapy. Dosing for the nicotinicreceptor modulator may be found by routine experimentation. For annicotinic receptor agonist, e.g., nicotine, typical daily dose rangesare, e.g. about 1-5000 mg, or about 1-3000 mg, or about 1-2000 mg, orabout 1-1000 mg, or about 1-500 mg, or about 1-100 mg, or about 10-5000mg, or about 10-3000 mg, or about 10-2000 mg, or about 10-1000 mg, orabout 10-500 mg, or about 10-200 mg, or about 10-100 mg, or about20-2000 mg or about 20-1500 mg or about 20-1000 mg or about 20-500 mg,or about 20-100 mg, or about 50-5000 mg, or about 50-4000 mg, or about50-3000 mg, or about 50-2000 mg, or about 50-1000 mg, or about 50-500mg, or about 50-100 mg, about 100-5000 mg, or about 100-4000 mg, orabout 100-3000 mg, or about 100-2000 mg, or about 100-1000 mg, or about100-500 mg. In some embodiments, the daily dose of nicotine is about 1,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300, 400, 500, 600,700, 800, 900, or 1000 mg. In some embodiments, the daily dose ofnicotine is 0.9 mg. In some embodiments, the daily dose of nicotine is1.8 mg. In some embodiments, the daily dose of nicotine is 2.4 mg. Insome embodiments, the daily dose of nicotine is 3 mg. In someembodiments, the daily dose of nicotine is 6 mg. In some embodiments,the daily dose of nicotine is 7 mg. In some embodiments, the daily doseof nicotine is 8 mg. In some embodiments, the daily dose of nicotine is9 mg. In some embodiments, the daily dose of nicotine is 12 mg. In someembodiments, the daily dose of nicotine is 14 mg. In some embodiments,the daily dose of nicotine is 18 mg. In some embodiments, the daily doseof nicotine is 21 mg. In some embodiments, the daily dose of nicotine is24 mg. In some embodiments, the daily dose of nicotine is 32 mg. In someembodiments, the daily dose of nicotine is 50 mg. In some embodiments,the daily dose of nicotine is less than 93 mg. Daily dose range maydepend on the form of nicotinic receptor agonist and/or factors withwhich the nicotinic receptor agonist is administered, as describedherein.

In some embodiment the daily dose of nicotine is such that the plasmalevel of nicotine or a nicotine metabolite is about 1 pg/ml to about 1mg/ml. In some embodiments the daily dose of nicotine is such that theplasma level or nicotine or nicotine metabolite is about 1 pg/ml toabout 1 ng/ml, or about 50 pg/ml to about 1 ng/ml, or about 100 pg/ml toabout 1 ng/ml, or about 500 pg/ml to about 1 ng/ml, or about 1 ng/ml toabout 500 ng/ml, or about 10 ng/ml to about 500 ng/ml, or about 100ng/ml to about 500 ng/ml, or about 200 ng/ml to about 500 ng/ml, orabout 300 ng/ml to about 500 ng/ml, or about 400 ng/ml to about 500ng/ml, or about 500 ng/ml to about 1 ug/ml, or about 600 ng/ml to about1 ug/ml, or about 700 ng/ml to about 1 ug/ml, or about 800 ng/ml toabout 1 ug/ml, or about 900 ng/ml to about 1 ug/ml, or about 1 ug/ml toabout 1 mg/ml, or about 10 ug/ml to about 1 mg/ml, or about 100 ug/ml toabout 1 mg/ml, or about 500 ug/ml to about 1 mg/ml, or about 600 ug/mlto about 1 mg/ml, or about 700 ug/ml to about 1 mg/ml, or about 800ug/ml to about 1 mg/ml, or about 900 ug/ml to about 1 mg/ml. In someembodiment, the daily dose of nicotine is such that the plasma level ofnicotine or a nicotine metabolite is about 200 ng/ml to about 420 ng/ml.In some embodiment, the daily dose of nicotine is such that the plasmalevel of nicotine or a nicotine metabolite is about 1 ng/ml to about 20ng/ml. In some embodiment, the daily dose of nicotine is such that theplasma level of nicotine or a nicotine metabolite is about 1 ng/ml toabout 5 ng/ml. In some embodiment, the daily dose of nicotine is suchthat the plasma level of nicotine or a nicotine metabolite is about 20ng/ml to about 100 ng/ml.

When a nicotinic receptor modulator, e.g., an agonist such as nicotine,is administered in a composition that comprises one or more dopaminergicagents and the dopaminergic agent has a shorter half-life than nicotinicreceptor modulator, unit dose forms of the dopaminergic agent and thenicotinic receptor modulator may be adjusted accordingly.

EXAMPLES Example 1 Nicotine Reduced Levodopa-Induced Dyskinesias inMonkeys with Nigrostriatal Damage Materials and Methods

Animals: Squirrel (Saimiri sciureus) monkeys (n=7) were purchased fromWorld Wide Primates (Miami, Fla.). The animals weighed between 0.6-0.9kg and were in mid to late adulthood as determined from their generalappearance (dentition, fur, other). Female monkeys were used since olderanimals were available that may better model Parkinson's disease. Theanimals were placed in quarantine upon arrival, and maintained in atemperature-controlled room (27±3° C.) with a relative humidity >30%,under a 13/11-hour light/dark cycle. Monkey food chow andfruits/vegetables were provided once daily, with water provided adlibitum. The monkeys were housed in separate cages to allow for clearbehavioral assessments. The animals were released from quarantine after1 month and treatments initiated. All procedures conformed to theNational Institutes of Health Guide for the Care and Use of LaboratoryAnimals and were approved by the Institutional Animal Care and UseCommittee at the Parkinson's Institute.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration:Prior to lesioning, the animals were allowed to acclimate to the colonyand rated for parkinsonism as described (Langston et al. Ann Neurol.2000; 47:579-89). All values were within the normal range. The monkeyswere then injected subcutaneously with 2.0 mg/kg MPTP (Sigma, St-Louis,Mo.) dissolved in saline. The animals were rated for parkinsonism 3-4weeks after MPTP administration. The disability scores ranged from 0(normal) to 28 for a severely parkinsonian animal. Animals were assessedfor 1) spatial hypokinesia (reduction in use of the available cagespace), 2) body bradykinesia (increased slowness in body movement), 3)left and 4) right manual dexterity, 5) balance, 6) freezing and 7)action tremor. If they were not parkinsonian, MPTP injection (1.0-2.0mg/kg) was repeated from 2-5 times for total doses of 3.5 to 13.5 mg/kg.Despite multiple MPTP dosing, two of the animals were not stablyparkinsonian. These two monkeys did exhibit reliable dyskinesias inresponse to levodopa treatment.

Nicotine treatment: All monkeys (n=7) were then given a drinkingsolution for 3 weeks consisting of commercially available orangeGatorade® to mask nicotine's bitter taste (FIG. 1). The control group(n=4) was continued on Gatorade® only, while nicotine (free base) wasadded to the Gatorade of the treated group (n=3). Nicotine dosing wasstarted at 50 μg/ml for 1 week, 150 μg/ml for 1 week, with theconcentration increased by 150 μg increments/week over the next fewweeks, up to 650 μg/ml (FIG. 1). Since the animals were relatively oldand exhibited poor dentition, the dried food pellets were softened with˜25 ml of either Gatorade® or the nicotine-Gatorade® (for the treatedanimals) to ensure adequate nicotine intake. There were no significanteffects of nicotine treatment on body weight or fluid intake, and themonkeys appeared in good health.

Levodopa administration: Monkeys were administered levodopa/carbidopa (5mg/kg and 1.25 mg/kg, respectively), prepared by crushing a tablet ofSinemet® CR 100/25 (DuPont Pharma) and dissolving it in water. This doseof levodopa is within the range of that prescribed to Parkinson'sdisease patients. The monkeys were gavaged twice daily at 3.5-hourintervals for 8 weeks at a time using a 5-day-on/2-day-off schedule (Hsuet al., J Pharmacol Exp Ther. 2004; 311:770-777). During levodopatreatment, the monkeys were given fruits in the morning and food pellets3.5 hours after the afternoon levodopa dose to optimize gastrointestinalabsorption.

Dyskinesias were rated from videotapes, as described (Hsu et al., JPharmacol Exp Ther. 2004; 311:770-777). This included a one hourbaseline period (no drugs) from ˜8:00-9:00 AM, followed by two 3.5-hourtreatment periods with levodopa starting at ˜9:00 AM and ˜12:30 PM.Dyskinesias were rated for 2-minute periods at 30-minute intervals bytwo independent raters blinded to treatment. They were rated on a scaleof 0 (no dyskinesias) to 4; a score of 1 was indicative of subtledyskinesias that were not sustained; 2, mild dyskinesias that weresustained; 3, moderate dyskinesias that impaired the ability to remainstationary; 4, severe dyskinesias that were generalized andincapacitating.

Data analyses: The levodopa treatment protocol used in the present studyinvolved a 5-day-on/2-day-off schedule. Parkinsonian ratings were doneon Monday and Friday of each week, with the score averaged over the twodays. Dyskinesias ratings were determined by averaging the scores onWednesday and Thursday of each week. All values are expressed as themean±SE of the indicated number of animals. Results were compared usingpaired t-tests or analysis of variance (ANOVA) followed by Bonferronimultiple comparison post hoc test, using Prism® program (GraphPadSoftware, Inc, San Diego, Calif.). A level of 0.05 was consideredsignificant.

Measurement of plasma cotinine levels: Plasma cotinine, a major (75%)nicotine metabolite, was measured as an index of nicotine intake(Hukkanen et al., Pharmacol Rev. 2005; 57:79-115 and Matta et al.,Psychopharmacology (Berl). 2007; 190:269-319). Blood (1-2 ml) was drawnfrom the femoral vein under ketamine sedation (15-20 mg/kgintramuscularly) at ˜3 PM. The blood samples were centrifuged at 1,000×gfor 12 minutes, and the plasma stored at −80° C. Plasma cotinine levelswere measured using an ELISA kit (OraSure Technologies Inc, Bethleham,Pa.). Plasma cotinine levels were 303+25 (n=7), and fell within therange observed in cigarette smokers (Hukkanen et al., Pharmacol Rev.2005; 57:79-115 and Matta et al., Psychopharmacology (Berl). 2007;190:269-319).

Results

Time course of the nicotine-induced decline in levodopa-induceddyskinesias in monkeys with nigrostriatal damage: Nicotine treatment(n=3) resulted in a reduction in levodopa-induced dyskinesias over thecourse of the day as compared to non-nicotine-treated animals (n=4).This decline was observed over the entire 8-week period investigated,with the data for weeks 2, 4, 6 and 8 depicted in FIG. 2. In monkeys notreceiving nicotine, dyskinesias developed rapidly following levodopaadministration, were maximal after 30-90 minutes, and declined over theremaining two hours (FIG. 2). Dyskinesias were significantly reduced innicotine-treated animals compared to monkeys not receiving nicotine. Forinstance at 8 weeks, ANOVA yielded a significant main effect of nicotinetreatment (F[1, 80]=54.24, p<0.0001). There also was a significant maineffect of time (F[15, 80]=8.95, p<0.0001).

Decline in total dyskinesias in monkeys receiving nicotine treatment: Itwas next examined the effect of nicotine treatment on the totaldyskinetic response by evaluating the area under the curve of the timecourse. A significant decrease was observed in nicotine-treated animalsat all time points compared to monkeys not receiving nicotine (FIG. 3).For instance at the 8 week time point, there was a significant maineffect of nicotine by ANOVA (F[1, 10]=11.41, p=0.007), with no effect oftime.

Nicotine treatment decreases peak dose dyskinesias: Peak dyskinesias,defined as the maximal dyskinetic score during the morning or afternoon,were decreased throughout the 8-week levodopa treatment period innicotine-treated animals compared to control (FIG. 4). For instance at 8weeks, there was a significant main effect of nicotine by ANOVA (F[1,10]=7.90, p=0.0184), with no main effect of time.

Nicotine shortened the duration of dyskinesias: Dyskinesias were stillevident in the non-nicotine-treated monkeys 3 hours after the seconddaily levodopa administration, but not in animals treated with nicotine(FIG. 2, Table 1). ANOVA showed there was a main effect of nicotinetreatment (F [1, 20]=18.33, p=0.0004), but not time indicating nodifference across the 8-week rating period (Table 1).

TABLE 1 Nicotine administration shortens the duration oflevodopa-induced dyskinesias Nicotine Week of levodopa treatmentTreatment N 2/3 4 6 8 No 4 0.5 ± 0.3 1.0 ± 0.4 1.1 ± 0.2 0.9 ± 0.1 Yes 30.3 ± 0.3 0* 0* 0.2 ± 0.2 Each value is the mean ± SE of dyskineticratings 3 hours after the afternoon levodopa treatment. *p < 0.05 ascompared to no nicotine treatment using ANOVA followed by a Bonferronipost-hoc test.

Example 2 Nicotine Reduced Dyskinesias in Levodopa-Primed MonkeysMaterials and Methods

Materials and methods were the same as in example 1.

Results

Crossover study: The data depicted in FIG. 2-4 and Table 1 clearlyshowed that nicotine administration attenuated levodopa-induceddyskinesias. A crossover study, was then conducted, in which the animalsoriginally receiving nicotine were given vehicle (n=3), while thevehicle-treated animals were now administered nicotine (n=4). Levodopatreatment was stopped. The concentration of nicotine was graduallyincreased in the drinking water (see FIG. 1) to 650 μg/ml, at which theanimals were maintained for 4 weeks. Monkeys that had previouslyreceived nicotine were placed on vehicle drinking water for the sametime period. All monkeys were then treated with levodopa (5 mg/kg, twicedaily 3.5 hours apart) for a subsequent 8-week period. Since both groupsof monkeys had previously received levodopa, they were termedlevodopa-primed.

Nicotine administration decreased levodopa-induced dyskinesias inlevodopa-primed monkeys: For these analyses, the ratings obtained foreach animal on the new treatment were compared to the score of the sameanimal in the previous treatment period, that is, prior to crossover.The results in FIG. 5 show that nicotine administration significantlyreduced total dyskinesias at all time points using paired t-tests.Analyses of the dyskinetic time course also showed a main effect ofnicotine throughout levodopa treatment by ANOVA (for example, week 8,F[1, 114]=15.89, p=0.0001). Peak dyskinesias were significantly reducedduring the last 4 weeks of levodopa treatment (week 6, p=0.0354; andweek 8, p=0.0138 by paired t-tests). There was also a decrease in theduration of dyskinesias with nicotine treatment, with a significant maineffect of nicotine by ANOVA (F [1, 24]=18.00, p=0.0003). Thus, nicotineadministration reduced levodopa-induced dyskinesias in animalspreviously exposed to levodopa.

Removal of nicotine increases levodopa-induced dyskinesias inlevodopa-primed monkeys: By contrast, in animals removed from nicotinetreatment, total dyskinetic scores were significantly enhanced at week4, 6 and 8 of levodopa treatment (FIG. 6). Analyses of the time courseof dyskinesias also showed an increase in dyskinesias over the 8-weeklevodopa treatment, with ANOVA yielding a significant main effect ofnicotine (for example, week 8, F [1, 76]=15.94, p=0.0001). In addition,there was a significant increase in the duration of dyskinesia assessed3 hours after the afternoon levodopa dose, with a significant maineffect of nicotine by two-way ANOVA (F [1, 16]=5.33, p=0.0346). Thus,removal of nicotine enhanced levodopa-induced dyskinesias.

Nicotine administration does not affect parkinsonism on or off levodopatreatment: Levodopa administration reduced parkinsonism ratings, whichwere measured 1.5-2 hours after levodopa dosing when its effects aremaximal (FIG. 7 and Table 2). Nicotine treatment did not affectparkinsonism either on of off levodopa treatment (F [1, 16]=0.03,p=0.8718).

TABLE 2 Nicotine administration does not affect parkinsonism on or offlevodopa treatment Parkinson Ratings levodopa Nicotine Mean ± SETreatment Treatment Expt 1 Expt 2 (crossover) (n) No No 3.7, 6.1, 6.06.8, 7.4 6.0 ± 0.6 (5) No Yes 5.2, 6.6 4.1, 6.4, 5.9 5.6 ± 0.5 (5) YesNo 0.4, 0.4, 0.6 1.8, 0.9 0.8 ± 0.3 (5) Yes Yes 1.7, 1.5 0.8, 0.4, 0.81.0 ± 0.2 (5)

FIG. 7 shows the effect of nicotine administration on parkinsonism.White bars indicate no nicotine treatment and black bars indicatenicotine treatment. Parkinsonism was evaluated immediately before theafternoon L-dopa dose and 1.5 to 2 hours after L-dopa treatment, when amaximal antiparkinsonian effect is anticipated. Two of the seven animalsin the study were not parkinsonian, and therefore were not included inthis analysis. Error bars are the means±standard error of five animalsbefore and after crossover of nicotine treatment. **p<0.01, as comparedwith the same group with no L-dopa treatment by a Mann-Withney test.These results suggest that nicotine treatment influenced only dyskineticbehavior and not parkinsonism.

The results from example 1 and 2 are the first to show that nicotinetreatment attenuates levodopa-induced dyskinesias in nonhuman primates.Nicotine treatment significantly reduced both the peak and duration ofthe dyskinetic response. Importantly, this was not accompanied by aworsening of parkinsonism either on or off levodopa. In animalspretreated with nicotine, that is, levodopa naïve monkeys, there was˜60% decline in levodopa-induced dyskinesias. In addition, nicotinetreatment reduced dyskinesias by ˜35% in monkeys that had receivedpreviously been treated with levodopa, that is, in levodopa-primedmonkeys.

Example 3 Effect of Continuous Delivery of Nicotine on itsAntidyskinetic Effect

Animals: Two groups of experimental animals (see Table 3) are requiredfor these experiments to determine the effectiveness of minipumpadministration in reducing dyskinesias in lesioned monkeys

TABLE 3 Groups for experiments in example 3 L-dopa treatment Groups nNicotine (5 mg/kg orally) (1) MPTP-lesioned 8 No Yes (2) MPTP-lesioned 8Yes Yes

MPTP treatment. All animals are lesioned with an injection of MPTP(1.5-2.0 mg/kg, sc). The animals are rated for parkinsonism 3-4 weeksafter lesioning according to methods described in example 1. If ananimal is not parkinsonian, MPTP injection will be repeated up to 4times. The lesioning process may therefore require up to 4 months togenerate animals with parkinsonism. Eight animals are required per groupas our objective is to obtain stably parkinsonian animals. In general˜80% of the animals develop stable parkinsonism. The animals are thenallowed to recover from the last MPTP injection for 1 month to ensurethey are stably parkinsonian before the minipumps are surgicallyimplanted.

Minipump delivery: Nicotine is delivered via a minipump according tostandard procedure, using the 0.2 ml pump (ALZET) to release nicotineover a 4-week period. Nicotine is administered at a dose of 0.5mg/kg/day (free base). This dose is chosen based on previous data innonhuman primates known in the art. Surgically implanted minipumpscontaining nicotine and the treatment appears to be well tolerated, withno appreciable weight loss or adverse effects. The non-nicotine treatedgroup will receive vehicle in the pump. Plasma nicotine and cotininelevels will be measured 1-2 weeks after minipump implantation to ensureadequate nicotine dosing as described in example 1. The objective is toachieve levels similar to those in our current study involving nicotineadministration in the drinking water (˜500 ng/ml). The pumps arereplaced monthly to ensure that the supply of nicotine remains constant.The animals receive nicotine for 2 months prior to the initiation ofL-dopa treatment.

L-Dopa: After 2 months of nicotine infusion, both groups of monkeys(either vehicle or nicotine) are gavaged with L-dopa/carbidopa (5mg/kg/1.25 mg/kg) twice daily at 9:00 AM and 1:00 PM. Treatment isperformed on a 5-day-on 2-day-off schedule and is done for at least 4weeks. If nicotine treatment reduces dyskinesias, L-dopa treatment iscontinued (up to 2 months) to allow us to determine how long thedecrease in dyskinesias is maintained.

Parkinsonism will be rated using a modified nonhuman primateparkinsonian rating scale as described in example 1. Dyskinesias aremonitored from videotapes, using the rating system detailed inexample 1. Parkinsonian ratings are done throughout the entire treatmentperiod (˜9 months) 3 times weekly. Dyskinesia ratings are done when theanimals are being treated with L-dopa.

These studies will test the effect of constant nicotine administrationwhich may enhance the antidyskinetic effect of nicotine. Without beinglimited to any theory, continuous nicotine application results in aninitial receptor activation that is followed by receptor desensitizationor inactivation that remains until the nicotine dissipates. Receptordesensitization or blockade is then thought to result in compensatorychanges in striatal nAChRs, with the receptor changes possibly beingmore pronounced depending on the period of desensitization. Thus, onemight expect a more sustained-desensitization and receptor changes withcontinuous nicotine treatment.

Example 4 Nicotine Treatment Reduces L-Dopa-Induced Dyskinetic-LikeMovements in Rats Materials and Methods

Animal model-6-Hydroxydopamine lesioning. We used the 6-hydroxydopaminelesioned rat model of nigrostriatal damage described by Cenci andcolleagues (Cenci et al., 1998 Eur J Neurosci 10:2694-2706; Cenci etal., 2002 Nat Rev Neurosci 3:574-579). Adult male Sprague-Dawley ratswere anesthetized with isofluorane, and then placed in a Kopfstereotaxic instrument. Burr holes were drilled through the skull and anintracranial injection of 6 μg 6-hydroxydopamine (2 μg/μl)stereotaxically injected at two separate sites into the right ascendingdopamine fiber bundle, for a total of 12 μg 6-hydroxydopamine. Thecoordinates for the position of these two lesion sites were as followsrelative to the Bregma and dural surface: (1) anteroposterior, −4.4;lateral, 1.2; ventral, 7.8; tooth bar at −2.4; (2) anteroposterior,−4.0; lateral, 0.75; ventral, 8.0; tooth bar at +3.4 (Cenci et al., 1998Eur J Neurosci 10:2694-2706; Cenci et al., 2002 Nat Rev Neurosci3:574-579). All procedures conformed to the NIH Guide for the Care andUse of Laboratory Animals and were approved by the Institutional AnimalCare and Use Committee.

Behavioral assessment of the lesion. As an index of nigrostriataldamage, the rats were tested for rotational behavior 3 and 4 weeks afterlesioning. This was done using an automated behavioral measurementapparatus that has four cylindrical chambers (50 cm height×34 cmdiameter) (ROTOMAX, AccuScan Instruments Inc. Columbus, Ohio, USA). Arat was placed in one of the chambers for 30 min for acclimatization,after which time amphetamine (4 mg/kg ip) was administered as previouslydescribed (Visanji et al., 2006, Neuropharmacology 51:506-516). The ratswere observed for circling behavior for 90 min after injection. The ratswere tested a second time one week later and the data from the twotesting periods pooled.

Nicotine treatment regimen. The rats were first given a drinkingsolution containing 1% saccharin for 3-4 days (FIG. 8). Nicotine wasthen added at a concentration of 25 μg/ml, and increased to 50 μg/ml 3-4days later. Animals were maintained on this dose for 3 weeks. L-dopatreatment was then initiated, as below, with the nicotine dosingcontinued.

L-dopa treatment and behavioral testing for AIMs. Rats received singledaily intraperitoneal injections of 8 mg/kg L-dopa methyl ester plus 15mg/kg benserazide for 3 weeks (FIG. 8), as described (Cenci et al., 1998Eur J Neurosci 10:2694-2706; Cenci et al., 2002 Nat Rev Neurosci3:574-579). Abnormal involuntary movements (AIMs) after daily LDOPAinjection were then quantified using the scale developed by Cenci andcolleagues (Cenci et al., 1998 Eur J Neurosci 10:2694-2706; Cenci etal., 2002 Nat Rev Neurosci 3:574-579), as previously done in ourlaboratory (Cox et al., 2007, Exp. Neurol.). Rats were placed in aRotomax test chamber. They were then scored on a scale from 0 to4:1=occasional; 2=frequent; 3=continuous but interrupted by sensorydistraction; 4=continuous, severe, not interrupted by sensorydistraction. The rating categories were as follows; (1) axial dystonia,consisting of twisting posturing of the head and neck; (2) orolingualdyskinesia, with stereotyped jaw movements and contralateral tongueprotrusion and (3) forelimb movements, with dystonic movements of thecontralateral forelimb. They were also assessed for locomotivedyskinesia, or increased locomotion with contralateral side bias;however, these scores were not included because the interpretation ofthis motor response is not clear (Papa et al., 1994 Brain Res 662;69-74; Cenci et al., 1998 Eur J Neurosci 10:2694-2706).

Locomotive dyskinesias are distinct from turning behavior describedabove. Rats were observed individually every 20 min for 3 h followingL-dopa treatment. The maximum possible score in each session was thus108 (maximum score per observation=12; number of observations persession=9). Rats were evaluated by two raters, one blinded to treatment.

Data analyses. Statistical significance was determined using Student'st-tests or ANOVA followed by Bonferroni post hoc tests, as appropriate.Data are mean±SEM. A p level of 0.05 was considered significant.

Results

Nicotine treatment reduces total AIM scores. The time course of theeffect of 50 μg/ml nicotine on the total number of AIMs after 3 weeks ofL-dopa treatment is shown in FIG. 9 (left panel). Each value in FIG. 9represents the mean±SEM of 9-10 rats. *p<0.05 using a Bonferroni posthoc test. A reduction in AIMs scores was observed throughout the entire3-hour period, with a significant main effect of nicotine treatment (F(1, 153)=15.83, p=0.0001) and time (F (8, 153)=4.12, p=0.0002), with nosignificant interaction (F (8,153)=0.388, p=0.93). Experiments were nextdone to determine whether a lower dose of nicotine also decreased AIMs.The nicotine concentration in the drinking water was therefore reducedfrom 50 to 25 μg/ml with continued L-dopa administration (see FIG. 8).The rats were tested for AIMs two and four weeks after initiation of thelower dose of nicotine (25 μg/ml). Since results at two and four weekswere similar, the data were pooled. FIG. 9 (right panel) shows that thenicotine-induced reduction in AIMs was sustained using 25 μg/ml nicotinein the drinking water. Two-way ANOVA demonstrated a significant maineffect of nicotine treatment (F (1, 153)=35.32, p<0.0001) and time (F(8, 153)=2.06, p=0.0428), with no significant interaction (F (8,153)=0.41, p=0.92).

Nicotine treatment reduces different AIM components. As indicatedearlier, AIMs consist of several different components including (1)axial dystonia; (2) orolingual dyskinesia; and (3) limb dyskinesia.Results shown are for the 3 and 6-8 week time points (FIG. 10). Eachvalue of FIG. 10 represents the mean±SEM of 9-10 rats, *p<0.05 and**p<0.01 using a t-test. There were significant decreases in forelimbdyskinesias at both time points with both doses of nicotine, and inaxial dyskinesias at the 6-8 week time point. There was a trend for adecrease in oral dyskinesias, although this was not significant. Thus,nicotine treatment reduces some AIMs, but not others. These results mayimply that nicotine differentially affects molecular mechanisms linkedto AIMs. To evaluate this possibility, correlation analyses can be donebetween nicotine-mediated reduction in AIMs components and molecularmechanisms.

Effect of nicotine on behavior related to parkinsonism. Our studies inmonkeys showed that nicotine treatment reduced L-dopa-induceddyskinesias without affecting parkinsonism. In our preliminary studiesin rats, we found that nicotine treatment did not affect turningbehavior, which is used as an index of nigrostriatal damage (Mabandla etal., 2004 Metab Brain Dis 19; 43-50; Howells et al., 2005 Behav BrainRes 165:210-220; Steiner et al., 2006 Exp Neurol 199:291-300). Theextent of turning was quantified using the ROTOMAX, AccuScan System,with no difference between rats receiving saccharin (8.2+3.7, n=10)compared to nicotine (8.4+6.7, n=9). The effect on nicotine on rotarodperformance can also be tested. This is another approach used toevaluate effects of drugs on motor performance in parkinsonian rats(Lundblad et al., 2003 J Neurochem 84:1398-1410; Dekundy et al., 2007Behav Brain Res 179:76-89).

The present data show that nicotine treatment significantly reducesL-dopa-induced AIMs in a 6-hydroxydopamine-lesioned rat model. Theydemonstrate a decline in AIMs at nicotine doses of 25 and 50 μg/ml inthe drinking water. This effect of nicotine persists with at least 2months of L-dopa treatment. These results are important as they furthersupport the idea that nicotine may be useful for the treatment ofL-dopa-induced dyskinesias in Parkinson's disease.

Example 5 Effects of Nicotinic Receptor Agonist on L-Dopa-InducedDyskinetic Movements

The effect of nicotinic receptor agonist such as conotoxinMII,epibatidine, A-85380, cytisine, lobeline, anabasine, SIB-1508Y,SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403,SSR180711, GTS-21 and varenicline can be tested using the modelsdescribed in the previous examples. The effect of nicotinic receptoragonist in L-dopa-induced dyskinesias can be tested in the rodent modeldescribed in Example 4. The compounds can in addition be tested in anonhuman primate model, which exhibits parkinsonian symptoms anddyskinesias that closely resemble those in Parkinson's disease such asthe model described in Examples 1-3. Nicotinic receptor agonist can betested using both models. Alternatively, nicotinic receptor agonist canbe tested using either one of the models described herein as well as anymodel known in the art.

Rodent Model

6-Hydroxydopamine lesion. Rats (30) can be first be lesioned with6-hydroxydopamine as described in Example 4.

Behavioral assessment of the lesion. As an index of nigrostriataldamage, the rats will be tested for rotational behavior two (2) weeksafter the lesion. This will be done using an automated behavioralmeasurement apparatus. Baseline activity will be monitored for thirty(30) minutes, after which time amphetamine (4 mg/kg i.p.) will beadministered. Because amphetamine induces a greater dopamine releasefrom the unlesioned as compared to the lesioned striatum, the animalsturn to the ipsilateral side. Rotation will be monitored for ninety (90)minutes. The rats will be retested one (1) week later, and the resultsfrom the two (2) testing periods pooled. Rats with scores over 100rotations will be retained for further study (generally 20-25 animalsout of 30).

L-dopa treatment. Rats (20) can be injected i.p. with 8-12 mg/kg L-dopamethyl ester plus 15 mg/kg benserazide once daily for three (3) weeksand longer (Cenci et al., 1998 Eur J Neurosci 10:2694-2706.; Cenci etal., 2002 Nat Rev Neurosci 3:574-579). Three (3) weeks of L-dopatreatment results in the development of AIMs in the majority of rats.L-dopa dosing will be started after the nicotinic agonist treatment.

Evaluation of L-dopa-induced AIMs. L-dopa-induced AIMs can be quantifiedas described in Example 4 (Cenci et al., 1998 Eur J Neurosci10:2694-2706.; Cenci et al., 2002 Nat Rev Neurosci 3:574-579; Cox etal., 2007 Exp Neurol). This includes axial dystonia, orolingualdyskinesia and forelimb movements with rats scored on a scale from 0 to4 for each AIM component. Rats will be observed individually everytwenty (20) minutes for three (3) hours following L-dopa treatment. Themaximum possible score in each session is thus 108 (maximum score perobservation=12; number of observations per session=9). Two raters, oneblinded to treatment, will evaluate the rats.

Nicotinic agonist regimen. The agonists can be administered 2-3 weeksprior to L-dopa treatment, preferably in the drinking water. The optimaldose and route of agonist administration will need to be determinedprior to initiation of the experiments with lesioned animals. If thisinformation is not available, pilot studies can be done to determineoptimal dosing.

Evaluation of parkinsonism. Amphetamine and L-dopa-induced contralateralturning will be evaluated as described above to determine the effects onparkinsonism.

Treatment. All thirty (30) rats can be first lesioned with6-hydroxydopamine over a one (1) week period. They can be tested 2 and 3weeks later to determine the extent of nigrostriatal damage byevaluating ipsilateral turning in response to amphetamine (20-25 ratsacceptable rotation). One (1) week is usually required to evaluateturning behavior in the animals; behavioral testing of 20-25 ratsusually takes two (2) weeks. At week 4, Group 1 will be given vehicle(e.g. saccharin) only. Group 2 will be given vehicle (possiblysaccharin) plus agonist. L-dopa plus benserazide will then beadministered two (2) weeks after agonist is started. AIMs are determinedthree (3) weeks after the start of L-dopa administration. L-dopatreatment will be continued throughout.

Non Human Primate Model

Although rats are an excellent model for screening compounds, nonhumanprimate studies ensure efficacy in a model that more closely resembleshuman Parkinson's disease. The experiments can be designed to furtherrefine the understanding of the dosing and mode of the nicotinicreceptor agonist administration that will be most effective. The nonhuman primate model described in Examples 1 and 2 can be used to testthe effect of nicotinic receptor agonist in L-dopa induced dyskinesias.

The effect of continuous delivery of the nicotinic receptor agonist onL-dopa induced dyskinesias can be tested via minipump as described inExample 3.

Example 6 Intermittent and Continuous Nicotine Treatment ReduceL-Dopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease Methods

Animals. Experiments were performed using male Sprague-Dawley rats(initial weight ˜250 g) purchased from Charles River Laboratories(Gilroy, Calif.). They were housed 2 per cage under a 12-12 h light-darkcycle in a temperature-controlled room with free access to food andwater. Three to four days after arrival, the rats were unilaterallylesioned with 6-hydroxydopamine as previously described (Cenci et al.,1998 Eur J Neurosci 10:2694-2706.; Cenci et al., 2002 Nat Rev Neurosci3:574-579). During the lesioning procedure the rats were maintainedunder isofluorane anesthesia (2%). They were placed in a Kopfstereotaxic instrument and burr holes drilled through the skull at thefollowing coordinates relative to the Bregma and dural surface: (1)anteroposterior, −4.4; lateral, 1.2; ventral, 7.8; tooth bar at −2.4;(2) anteroposterior, −4.0; lateral, 0.75; ventral, 8.0; tooth bar at+3.4 (Cenci et al., 1998 Eur J Neurosci 10:2694-2706.; Cenci et al.,2002 Nat Rev Neurosci 3:574-579). 6-Hydroxydopamine was dissolved in0.02% ascorbic acid/saline at a concentration of 3 ug/ul. Two μl wasstereotaxically injected at each of these sites for a total of 12 mginto the right ascending dopamine fiber bundle. Infusion of6-hydroxydopamine into the target area was over a 2-min period, with thecannula maintained at the site of injection for a further 2 min. Allprocedures conformed to the NIH Guide for the Care and Use of LaboratoryAnimals and were approved by the Institutional Animal Care and UseCommittee.

Behavioral testing. Two and three weeks after lesioning, rats weretested for rotational behavior in an automated behavioral measurementapparatus (ROTOMAX, AccuScan Instruments Inc. Columbus, Ohio, USA). Eachrat was placed in a cylindrical glass chamber for 30 min foracclimatization, after which amphetamine (4.0 mg/kg ip) wasadministered. The behavior was monitored for an additional 90 min, withrats making at least 100 ipsilateral turns used for further study.

Nicotine treatment. When the behavioral testing was completed, rats weretreated with nicotine via the drinking water that yields an intermittentdosing regimen or via minipump that provides a constant level ofnicotine. For administration via the drinking water, rats were firstprovided with a solution containing 1% saccharin (Sigma Chemical Co.,St. Louis, Mo.) to mask the bitter taste of nicotine. After 2-3 days ofacclimation, nicotine (free base, Sigma Chemical Co., St. Louis, Mo.)was added to the saccharin-containing drinking solution of the treatedgroup (pH 7.0). Nicotine was initially given at a concentration of 25μg/ml nicotine for 2 days. This was subsequently increased to 50 μg/mlnicotine, and animals maintained at this dose for several weeks (FIG.11). Measurement of fluid intake showed that animals with nicotine inthe solution drank less than their vehicle-treated counterparts, inagreement with previous studies in mice. The rats appeared healthyalthough there was a small difference in body weight with continueddosing.

In a separate series of experiments, rats were given nicotinecontinuously via Alzet minipumps (model 2004-200 μl), which secretenicotine for 28 days. These were subcutaneously implanted according tothe manufacturer's instruction. Pumps were filled with either sterilizedwater or nicotine base in water to deliver 2 mg/kg/d. Body weight wassimilar in the rats receiving minipumps containing either vehicle ornicotine (Table 4).

TABLE 4 Plasma cotinine levels in rats receiving chronic nicotine Number[Cotinine] Regimen Treatment Nicotine of rats ng/ml Drinking waterSaccharin  0 10  0 ± 0 Nicotine 50 μg/ml 9 987 ± 81 Nicotine 25 μg/ml 9303 ± 23 Minipump Water  0 12  0 ± 0 Nicotine  2 mg/kg/day 12 336 ± 49Values represent the mean ± SEM of the indicated number of animals.

L-dopa treatment. Three weeks after initiation of the 50 ug/ml nicotinedose, the rats received single daily intraperitoneal injections of 8mg/kg L-dopa methyl ester plus 15 mg/kg benserazide (both from SigmaChemical Co., St. Louis, Mo.) (Cenci et al., 1998 Eur J Neurosci10:2694-2706.; Cenci et al., 2002 Nat Rev Neurosci 3:574-579). After 3weeks of daily L-dopa dosing, abnormal involuntary movements (AIMs) werequantified. These included (1) axial dystonia, contralateral twistedposturing of the neck and upper body; (2) orolingual dyskinesia,stereotyped jaw movements and contralateral tongue protrusion; and (3)forelimb dyskinesia, repetitive rhythmic jerks or dystonic posturing ofthe contralateral forelimb and/or grabbing movements of thecontralateral paw (Cenci et al., 1998 Eur J Neurosci 10:2694-2706.;Cenci et al., 2002 Nat Rev Neurosci 3:574-579; Carta et al., 2006Neurochem 96:1718-1727). Rats were scored on a scale from 0 to 4 foreach of these three AIMs as follows: 1=occasional; 2=frequent;3=continuous but interrupted by sensory distraction; and 4=continuous,severe, not interrupted by sensory distraction. Animal behavior wasevaluated over 20 min sessions by two raters, one blinded to treatment,for 3 h following injections. This yielded a total of 9 sessions oftesting per animals. The maximum possible score for each animal was thus108 (maximum score per session=9; number of sessions over 3 h=12).

Plasma cotinine measurement. The nicotine metabolite cotinine wasdetermined as an indirect measure of plasma nicotine levels using anELISA kit (Orasure Technologies, Bethlehem, Pa.). Blood samples werecollected from the femoral vein after 1 to 2 wk after initiation ofnicotine treatment via the drinking water or minipump. Plasma wasprepared and a <1 μl aliquot used for assay according to themanufacturer's instructions. A standard curve ranging from 5 to 100ng/ml cotinine was done with every assay.

Data analyses. All analyses were done using GraphPad Prism® (GraphPadSoftware, Inc, San Diego, Calif.). Differences in rating scores betweengroups were analyzed using nonparametric tests (Mann-Whitney-Mann testor Wilcoxon test for paired data). For the time course studies, analysisof variance (ANOVA) followed by Bonferroni multiple comparison test wasused. A level of 0.05 was considered significant. Results are expressedas mean±SEM.

Results

FIG. 11 shows that intermittent nicotine treatment reducesL-dopa-induced abnormal involuntary movements (AIMs). Treatment schedule(top panel) depicting the time of administration of nicotine (indrinking water), L-dopa dosing and behavioral testing. Rats wereprovided with vehicle drinking water containing 1% saccharin for 1 week.Some of the rats (n=10) were continued on this solution, while nicotinewas added to the vehicle drinking water of the remaining animals (n=9).Nicotine administration was initiated at a dose of 25 μg/ml, and thenswitched to a final maintenance dose of 50 μg/ml. Three weeks later,they were given L-dopa (8 mg/kg ip) once daily for 10 weeks, and then 12mg/kg L-dopa for a further 5 weeks. AIMs were rated throughout theL-dopa treatment by two raters, one blinded to treatment. AIMs wererated as described in methods over a 3-hour period, including 30-min ofbaseline (no L-dopa). There was a significant effect (P<0.001) ofnicotine treatment on L-dopa-induced AIMS using ANOVA. Each symbol isthe mean±SEM of 9-10 rats.

FIG. 12 shows that intermittent nicotine treatment reduced individualAIM components after L-dopa treatment. Rats were given nicotine in thedrinking solution and subsequently administered L-dopa. The rats wereevaluated for total, axial, oral and forelimb AIMs by two raters, oneblinded to treatment status of the animals. Each value represents themean±SEM of 9-10 rats. *P<0.05, **P<0.01 and ***P<0.001 compared to ratsreceiving only saccharin using a Mann-Whitney test.

FIG. 13 shows a crossover study depicting the effect of intermittentnicotine treatment via the drinking water on L-dopa-induced AIMs. Theleft-hand panels depict results from rats that had initially received nonicotine prior to the first L-dopa treatment period, and weresubsequently given nicotine in the drinking solution as outlined in FIG.11. The right-hand panels depict results from rats that had initiallyreceived nicotine prior to the first L-dopa treatment period, and weresubsequently given saccharin in the drinking solution. Nicotineadministration reduced L-dopa-induced AIMS, while its removal resultedin an increase in AIMs development. Each value represents the mean±SEMof 9-10 rats. *P<0.05 and ***P<0.001 compared to the initial treatmentusing a Wilcoxon test.

FIG. 14 shows continuous nicotine exposure via minipump reducesL-dopa-induced AIMs. Treatment schedule (top) depicting the time ofadministration of nicotine (via minipump), L-dopa dosing and behavioraltesting. Half of the rats were implanted with minipumps containingnicotine (2 mg/kg/d) 4 weeks after 6-OHDA lesioning, and the other halfwith minipumps containing vehicle. Two weeks later, all the rats weregiven L-dopa (8 mg/kg ip) once daily for 4 weeks, and then 12 mg/kgL-dopa for a further 3 weeks. AIMs were rated throughout the L-dopatreatment by two raters, one blinded to treatment. The time course ofthe effect of nicotine on AIMs after L-dopa administration is depictedin the graph. AIMs were rated as described in methods over a 3-hourperiod, including 30-min of baseline (no L-dopa). There was asignificant effect (P<0.001) of nicotine treatment on L-dopa-inducedAIMs using ANOVA. Each symbol is the mean±SEM of 12 rats.

FIG. 15 shows that constant nicotine exposure via minipump reducedindividual AIM components after L-dopa treatment. Rats were givennicotine (2 mg/kg/d) via minipump and subsequently administered L-dopa.The rats were evaluated for total, axial, oral and forelimb AIMs by tworaters, one blinded to treatment status of the animals. Each valuerepresents the mean±SEM of 12 rats. *P<0.05, **P<0.01 and ***P<0.001compared to rats receiving no nicotine using a Mann-Whitney test.

FIG. 16 shows a crossover study depicting the effect of constantnicotine exposure via minipump on L-dopa-induced AIMs. The left-handpanels depict results from rats that had initially received no nicotineprior to the first L-dopa treatment period, and were subsequently givennicotine via minipump as depicted in FIG. 14. The right-hand panelsdepict results from rats that had initially received nicotine prior tothe first L-dopa treatment period, and were subsequently given minipumpscontaining no nicotine. Nicotine administration reduced L-dopa-inducedAIMs, while its removal resulted in an increase in AIMs development.Each value represents the mean±SEM of 12 rats. **P<0.01 and ***P<0.001compared to the initial treatment using a Wilcoxon test.

Example 7 Effects of Nicotinic Receptor Agonist on L-Dopa-InducedDyskinetic Movements in Humans

An empiric trial on the effects of nicotine on levodopa-induceddyskinesias can be conducted. Inclusion criteria include patients, bothmale and female, who suffered from Parkinson's disease that are 30 yearsold and older. The main inclusion criteria are: (i) Levodopa associatedpeak-dose dyskinesia which is at least moderately disabling and presentfor ≧25% of the waking day (UPDRS part IV, items 32 and 33, each ≧2)(ii) Levodopa associated end of dose deterioration, with an average‘Off’ time of 2.5 hours or more per day based on the pre-study patientdiary recordings between Days −4 to 2 9 (iii) Stable Parkinson'smedication for at least 1 month prior to randomization, with a minimumof 3 hours between the levodopa intakes (iv) Hoehn and Yahr Stages 1 to4 during ‘Off’ period (v) Demonstrated ability to comprehend and giveinformed consent (vi) Ability to complete patient diary. The mainexclusion criteria include: (i) Other clinically significant conditionsapart from those typically associated with Parkinson's disease (ii)Intake of medication associated with exacerbation of dyskinesia or withextrapyramidal side effects and tardive dyskinesia or induction of liverenzymes; neuroleptics; drugs used in treatment of cognitive impairment;or specified drugs known to be substantially metabolized through thefollowing cytochrome P450 isoenzymes: 1A2, 2B6, 2C19, 2C9, 2D6, and 2E1(iii) Use of St. John's Wort or Ginkgo Biloba within 48 hrs prior torandomization and until the last treatment day with the study medication(iv) Intake of an investigational drug within 30 days prior to InitialScreening

This study can be a multi-center, double-blind, placebo-controlled,multiple dose escalating, safety, tolerance, pharmacokinetics, andefficacy study of nicotine administered in Parkinson's disease patientswho are concomitantly being treated with a combination product oflevodopa and possible other antiparkinson medication. The patients willbe randomized into one of five treatment groups to receive either fixedor ascending doses of Nicotine (from 0.3 to 4 mg per dose) or placebo.For efficacy assessments, the patient is assessed with levodopachallenge, following an overnight withdrawal of Parkinson's medication.Levodopa-induced dyskinesia is assessed using a standardized ratingscale. Time spent in ‘Off’ state or in ‘On’ state without dyskinesia,with non-troublesome dyskinesia or with troublesome dyskinesia, isassessed using patient diaries (e.g. electronic patient diaries). Impactof dyskinesia on daily activities is quantified using a PDYS-26questionnaire. To explore potential positive or negative impact ofnicotine on cognitive functions, the study includes two cognitive tests.Finally, the study includes investigator assessments of CGI-I scales fordyskinesia, Parkinson's disease, and clinical condition in general.

Nicotine is compounded into capsules or tables and supplied to allsubjects. The patients will be treated as described in Table below

TABLE 5 Treatment Groups Group Assigned Intervention 1. Placebo Drug:Nicotine One placebo tablet administered from Day 1 to 35 Nicotine inoral formulation every time levodopa is administered to the subjects(~3-8 times per day) for up to 35 days 2. Active Comparator Drug:Nicotine One 0.3 mg tablet from Day 1 to 35 Nicotine in oral formulationevery time levodopa is administered to the subjects (~3-8 times per day)for up to 35 days 3. Active Comparator Drug: Nicotine One 0.3 mg tabletfrom Day 1 to 7, One 1 mg tablet Nicotine in oral formulation every timelevodopa is from Day 8 to 35 administered to the subjects (~3-8 timesper day) for up to 35 days 4. Active Comparator Drug: Nicotine One 0.3mg tablet from Day 1 to 7, One 1 mg tablet Nicotine in oral formulationevery time levodopa is from Day 8 to 14, One 2 mg tablet from Day 15 toadministered to the subjects (~3-8 times per day) for 21, One 1 mg andOne 2 mg tablets from Day 21 to up to 35 days 35 5. Active ComparatorDrug: Nicotine One 0.3 mg tablet from Day 1 to 7, One 1 mg tabletNicotine in oral formulation every time levodopa is from Day 8 to 14,One 2 mg tablet from Day 15 to administered to the subjects (~3-8 timesper day) for 21, One 1 mg and One 2 mg tablets from Day 21 to up to 35days 28, Two 2 mg tablets from Day 28 to day 35.

Subjects are instructed that concomitant medications should not bealtered without speaking with the investigator. Subjects are advisedthat they will be contacted every day or every other day to assessprogress in the trial and any side effects associated with the additionof nicotine. At the end of the trial, patients are interviewed. They areasked to rate their satisfaction with the study medication (−2-+2) andits ability to modulate the levodopa-induced dyskinesias. If the studyhas used placebo and is blinded, the blind is broken and statisticalcomparisons of nicotine versus placebo are performed.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

1-121. (canceled)
 122. A method for reducing drug-induced dyskinesiacomprising administering to a human in need of treatment with a drug anamount of a nicotinic receptor agonist sufficient to reduce dyskinesiainduced by said drug.
 123. The method of claim 122 wherein the amount ofnicotinic receptor agonist is sufficient to reduce said dyskinesia atleast about 30%.
 124. The method of claim 122 wherein said dyskinesia isinduced by a Parkinson's disease treatment.
 125. The method of claim 124wherein said Parkinson's disease treatment is a treatment with adopaminergic agent.
 126. The method of claim 125 wherein saiddopaminergic agent comprises a dopamine precursor or a dopamine receptoragonist.
 127. The method of claim 125 wherein said dopaminergic agentcomprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline,ropinorole, apomorphine or a combination thereof.
 128. The method ofclaim 127 wherein said dopaminergic agent is levodopa.
 129. The methodof claim 122 wherein said agonist is selected from the group consistingof a simple or complex organic or inorganic molecule, a peptide, aprotein, an oligonucleotide, an antibody, an antibody derivative, anantibody fragment, a vitamin derivative, a carbohydrate and a toxin.130. The method of claim 122 wherein said agonist is selected from thegroup consisting of nicotine, conotoxinM11, epibatidine, A-85380,cytisine, lobeline, anabasine, SIB-1508Y, SIB-1553A, ABT-418, ABT-594,ABT-894, TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21 and varenicline.131. The method of claim 130 wherein said agonist is nicotine
 132. Themethod of claim 122 wherein said nicotinic receptor agonist modulates anicotinic receptor comprising at least one a subunit or a nicotinicreceptor comprising at least one a subunit and at least one 13 subunit.133. The method of claim 132 wherein said α subunit is selected from thegroup consisting of α2, α3, α4, α5, α6, α7, α8, α9, and α10 and whereinsaid β subunit is selected from the group consisting of β2, β3 and β4.134. The method of claim 133 wherein said a subunit is selected from thegroup consisting of a β3, β4 and β6.
 135. The method of claim 132wherein said nicotinic receptor agonist modulates a nicotinic receptorcomprising subunits selected from the group consisting of β4β2, α6β2,α4α6β2, α4α5β2, α4α6β2β3, α6β2β3 and α4α2β2.
 136. The method of claim132 wherein said nicotinic receptor agonist modulates a nicotinicreceptor comprising subunits selected from the group consisting of α4and α7.
 137. The method of claim 122 wherein said subject suffers from acondition selected from the group consisting of Parkinson andAlzheimer's disease.
 138. The method of claim 137 wherein said conditionis Parkinson's disease.
 139. The method of claim 122 wherein saidadministration comprises a single dose of said nicotinic receptoragonist.
 140. The method of claim 122 wherein said administrationcomprises multiple doses of said nicotinic receptor agonist. 141-152.(canceled)
 153. The method of claim 122 wherein the administering ofsaid nicotine receptor agonist comprises oral administration.